annual report roche group annual report group account roche holding ltd basel annual account key figure millions chf roche group continue businessesa change change local local cur cur chf rency chf rency sale ebitdab operating profit exceptional item operating profit net income research development addition property plant equipment personnel number employee december ratio ebitdabas sale operating profit exceptional item sale operate profit sale net income sale research development sale datum share nonvoting equity security chf earning share nonvoting equity security dilute dividend share nonvoting equity securityc continue business include core pharmaceutical diagnostic business treasury corporate activity vitamin fine chemical division report discontinue business ebitda earning exceptional item interest financial income tax depreciation amortisa tion include impairment correspond operate profit exceptional item depreciation andamortisation include impairment dividend proposed board directorsgroup performance glance latot latot latot latot latot sale division millions chf pharmaceutical diagnostic vitamin fine chemical nonvoting equity security genussschein price performance chf roche nonvoting equity security adjust swiss market index rebase figure adjust basis figure continue business operate profit exceptional item figure fully comparable givaudan spinoff vitamin fine chemical demerger genentech transaction accounting policy change group figure net income millions chf net income share ebitda millions chf nonvoting equity security chf operating profit million chf research development millions chf addition property plant equipment million chf roche group annual report group account roche holding ltd basel annual account table content letter chairman board directors executive committee group performance group strategy division pharmaceutical diagnostic corporate governance finance financial review roche group consolidated financial statement note roche group consolidated financial statement report group auditor multiyear overview roche security roche holding ltd basel financial statement note financial statement appropriation available earning report statutory auditor roche global market presence table content goal improve people health quality life world roche scientist working discover innovative highquality solution unmet medical needsdoubledigit sale growth local currency pharmaceutical diagnostic increase market share profitability group operating profit grow fast sale net income healthy level hepatitis drug pegasys exceed expectation pharma pipeline substantially improve expand disetronic igen acquisition boost strength diagnostic division improvement corporate governance group separate sustainability report document broad commitment good corporate citizenship roche expect outpace market growth result exceptional itemsletter chairman dear shareholder roche group significant strategicoperational financial progress pharmaceutical diagnostic division record growth rate ahead respective marketsand thistogether increase profitability strong research development pipelinesconfirm strategy focus innovation tracknet income healthy leveland continued restructuring finance reduce group debt timewe enhance corporate governancethe board director propose dividend increase swiss franc share nonvoting equity security annual general meeting shareholder approvedthis group seventeenth dividend increase year letter chairmanwe please report sale diagnostic division grew achieve ambitious goal twice fast global invitro sale ofour pharmaceutical diagnostic market yearposting diagnostic division show dou healthy increase local curren bledigit increase local currenciesoperating profit exceptional item grow fast result excellent performance salesadvance local curren core business measure cie swiss francs bil lion swiss francsnet income ofour implement finance group core business reach billion considerably strong swiss francsfollowe net loss year core pharmaceutical diag ciesdue difficult economic nostic division grow fast conditionshoweverthe division fall marketsale pharmaceu short ofit goal ofachieve double tical division increase digit sale growthroche diagnostic local currency billion swiss expand market share francsthe integration ofchugai percentage point post sale japan contribute excellent billion francsthe division performancea growth ofour profitability show mark business new establish increasewith operating profit roche productswhich outpace margin exceptional item global marketroche expand improve percentage point global leadership oncology dur performance drive pri e company marily rapidly grow diabete anticancer product caremolecular diagnostic extend patient survivaland immunochemistry business file application mar kete approval ofa fourthavastin thanks success operat regulatory authority ing activitiesebitda core united states europethe market business increase local rollout ofour new hepatitis drug currency swiss franc pegasys progress toanimpressive billion swiss despite substantially high spending franc new drug launch novel hivaids drug fuzeon finance good progress highly promising restructuring reduce group project development pipeline debt yearachieve reduction pharmaceutical division contin billion swiss francswe ued improve profitabilityincrease improve risk profile ofour finan operating profit margin cial investment foreign exchange exceptional item transactionsthe share offinancial previous year asset hold equity reduce plannedneverthelessthe financial letter chairman statement net finan promising project cera anemia improve presentation cial expense ofaround million mabtherarituxan mra result line international swiss francsmainly continue rheumatoid arthritis financial reporting standard ifrs high interest expense enter final phase ofclinical devel improve comparability opment companiesroche replac result ofthe strong cash genera e dual reporting system adopt tion core business conclude new alliance actual adjust figure financial restructuringthe group primarily area ofbiotechnology single set offigure con financial condition considerably secure access promis solidate financial statement improvednet liquidity increase ing thirdparty innovation turn detail billion swiss francsand equity ratio include minority inter purchase ofdisetronic time annual report est improve end propose acquisition ofigen provide detail ofthe end mark important step compensation pay board roche diagnostic innovation strategy director member ofthe follow completion ofthe sale disetronic world second executive committeein additionwe vitamin fine chemical divi big maker ofinsulin pump create new function ofinde sion late septemberroche roche strengthen position pendent lead directorwhose main completely focused expand pioneer leader diabete man task lead board periodic core pharmaceutical diagnostic agementthe acquisition ofigen review ofthe chairman ceo business help shape expect complete mid performance chair board healthcare market ofthe future february secure roche member request ifthe chair man unable result extraordinary eventsthis represent convinced steer right course additional important step thecontinue evolution ofcorporate roche lead healthcare company governance roche annual general meeting partnership chugai rightsto key patentsallowe tap shareholder april significantly enhance roche mar new segment ofthe immuno mark number change ketpresence growth potential chemistry marketone ofthe division themembership boardthree injapanthe world secondlarg main growth areasandafter enter longserve member board pharmaceutical marketwe alliance affymetrix fritz gerberandre fleuenberger please progress ofthe start ofwe plan create henri bmei stepping productrelate collaboration entirely new market dna chip yearall roche chugaito develop mra clinical diagnosticsthis allow significant contribution devel treatment ofrheumatoid arthritis therapiesparticularly cancerto opment success rochethe tailor specifically genetic pro board director executive quality ofour pharmaceutical file ofdifferent patient group committee wish thank sin pipeline improve steadily cerely year dedi yearsat end continue evolve stand cat distinguished servicethe total new molecular entity ard ofcorporate governance board director propose werein developmentwe achieve transparency line national theelection bruno gehrig number ofclinical advance phase international regulation good lodewijk jrde vink new mem iiand important highly practice ofthe world company ber enhance letter chairmanboard independent andcritical operating divisionsour continued patient perspectivesubject hiselection profitability gain expand able achieve excellent result annual general meetingbruno global market leadership oncology gehrig appoint independent invitro diagnostic lead director strong development pipeline leave continue systematically implement strategy focus innovation independent com firmly believe longterm business success panyin order achieve long term success benefit patient possible policy practice aim doctorsour employee create value maintain economic social shareholder environmental sustainability good corporate citizenroche roche well equip sus haslong accept responsibility tainable organic growththe progress environment society strengthen new sustainability report conviction steer franz bhumer line commitmentfrom right course roche lead roche sustainability report healthcare company publish year annual reporti opportunity draw particularly proud ofinnova attention impressive range tive product hepatitis ofactivitie initiative describe drug pegasysthe hiv fusion inhi sustainability reportwe bitorfuzeonthe pioneer cancer firmly believe longterm business medicine avastin amplichip success possible poli cypthe world pharmaco cie practice aim create genomic testwhich help value maintain economic people enjoy significantly well social environmental sustain quality oflife ability extend life proud fact innovative product allow people enjoy significantly well quality life prolong life tight focus healthcare like express sincere andit extensive network ofalliance thank roche employee roche position meet commitmentprofessional challenge oftomorrow health ism hard workwithout care marketthe achievement ofour skill dedication service letter chairman board directors executive committee forthcoming change board shipfrom roche evolve traditionalhighly director propose appointment diversify company focus independent lead director healthcare groupmr gerber decision step director mark end strengthen roches corporate ofan era span yearsdure governance achieve key milestone significantly increase franz humer chairman board director ceo value ofour company current board term ofandreas board director oeri walter frey end fritz gerbers current term annual general meeting board end annual gentleman agree stand general meetingwhich hold reelection board april gerber decide time ago stand addition support reelec electionandre fleuenberger tion ofmr oeri freythe board henri bmeier likewise propose election ofbruno gehrig announce intention step switzerland lodewijk jrde directors timethe vink united states new board wish thank long board member stand member year ofdedicate distinguished take current position servicedure gerbers chairman chairman ofthe board ofdirector board director executive committeeboard directors franz humer january leave peter brabeckletmathe henri meier deanne julius andreas oeri horst teltschik john bell rolf hnggi fritz gerber andre leuenberger andr hoffmann walter frey year birth term end election board director franz humer chairman andre leuenberger vicechairman rolf hnggi vicechairman fritz gerber honorary chairman prof john bell peter brabeckletmathe walter frey andr hoffmann deanne julius henri meier andreas oeri horst teltschik secretary board directors gottlieb keller finance investment committee audit corporate governance committee remuneration committee nonexecutive member executive member committee chairman january board directors executive committee ofswiss life holdingbruno gehrig mrvilliger join roche holding gmbhbefore vicechairman ofthe governing andsignificantly strengthen appoint secretary board board ofthe swiss national bank expand human resource director compliance join organisation tenureunder officer january professor ofbusiness eco leadershipinitiatives head group function corpo nomic university ofst gallen roche connect employee equity plan rate serviceswhich comprise head swiss institute successfully introducedfrom corporate lawcorporate safety banking financeprofgehrig villiger environment corporate human begin career union bank responsible site service basel resourcesgottlieb keller retain switzerland kaiseraugst post secretary boardthe board ofdirector name andreas lodewijk jrde vink found markus altwegghead ofthe vitamin greutera lawyerto succeed keller member consultant ofblackstone fine chemical divisionsteppe compliance officermr greuter healthcare partnersbefore founding executive committee willhold post continue bhphe chairman ofglobal sale ofthe division com serve head ofcorporate auditing health care partnersa private equity pletedhe retired end unit ofcredit suisse boston year rochemr altwegg mrde vink year ofexpe member ofthe executive com rience pharmaceutical industry mittee nearly year begin career schering time significant contribu ploughwhere president tion success ofthe company ofschere international mov ofthe key people respon ing warnerlambert sible divisionalisation ofthe president chief previously highly centralised operating operate officerand chair businesseswas charge ofpharma manpresident ceo switzerlandand head ofvitamin fine chemicalsthe subject election annual board ofdirector wishes thank general meeting april markus altwegg distinguish bruno gehrig appoint inde service outstanding loyalty pendent lead director hewillcontinue serve roche member ofthe board ofdirector ifthe board proposal adopt offhoffmannla roche ltdbasel chairman ofthe board franz agroup operating company humer director serve executive capacity gottlieb akeller appoint head rocheand majority ofseat ofcorporate human resource board hold independent member ofthe executive committee director july kellerwho hold doctorate lawjoine roche member executive committee corporate law department daniel villigermember ofthe execu assistant tive committee head ofcorpo chairman ofthe boardin rate servicessteppe head ofhuman resource executive function july roche grenzach chairman ofthe inorder pursue personal interest executive board ofroche deutschland board director executive committeeexecutive committee january richard laube heino von prondzynski william burns franz humer erich hunziker jonathan knowles gottlieb keller year birth position executive committee franz humer chief executive officer erich hunziker chief financial officer control william burns pharmaceuticals division heino von prondzynski diagnostic division richard laube roche consumer health prof jonathan knowles research gottlieb keller corporate service secretary executive committee pierre jaccoud statutory auditor roche holding ltd ernst young ltd principal auditor jrg zrcher conrad lffel group auditor pricewaterhousecoopers principal auditor clive bellingham compliance officer andreas greuter direct phone number january board directors executive committee group performance group strategy aim lead healthcare company create produce market innova tive solution high quality unmet medical need product service help prevent diagnose treat disease enhance people health quality life group performance operating profit ofthe group togetherroche core pharmaceutical core business exceptional diagnostic business post item rise local currency salesgrowth local currency billion swiss francsthe growth swiss franc termssales rate swiss franc rise billion francsboth operating profit margin division grow fast respec basis improve furtherrising tive marketspharmaceutical sale result drive mainly division upper end ofthe profitabil oncology portfolionotably mabthera ity guidance issue rituxanherceptin xelodaand bythe newly launch hepatitis drug combine gross cash flow pegasys establish product core business strong cellcept neorecormonsale ebitda increase local roche diagnostic fuel currency swiss franc strong performance diabete billion billion swiss caremolecular diagnostic francsour ebitda margin increase immunochemistry business slightly percentage point group performance group strategygroup strategy new paradigm medicine mankind currently cure fraction ofall know disease enormous need real advance diagnostic therapeu ticshoweverbudget reality force government assess equivalentor betterhealth outcome attain low costin factno matter health system performpolicymaker payer industrialise coun try continuously exam ine way improve efficiency value money healthcare pharmaceutical diagnostic business successful focus healthcare rightthey work challenge change environment joint approach roche believe healthcare com make sound medicalhealth eco panie professional nomic business sense focus develop deploy targeteddifferentiate medical solu disease increasingly tionswhich case reduce define term oftheir molecular overall healthcare cost pathologyroche combination core competency lead researchdriven health importantparticularly care companyroche work rapidly evolve field like biotechnol way preserve restore health ogygeneticsgenomic proteomic capability diagnostic examplewe know cancer pharmaceutical enable innovate single entity broad spec entire healthcare spectrum trum ofdisease differ identify disease susceptibili significantly genetic tie disease screen popula area ofthe body affect tion risk preventiondiagnosis molecular diagnostic test identify therapy treatment monitoring difference lead way clinically differentiate medicine aim leader area weserveroche global market recent year roche imple leader diagnostic andas lead mente major strategic initiative like supplier ofprescription medicine integrate cancer care unit inselecte therapeutic area new roche biomarker program oncologyvirology transplanta leverage discovery synergies tionone ofthe pharmaceuti pharmaceutical diagnostic cal company division group performance group strategy ofour objective create focus innovation roche aportfolio ofbiomarker group network force drive enable effective identification ofthe progress target medicine patient respond good innovationroche pursue drug assess innovation strategy size disease progression improve drug countsroche approach safetyifparticipant clinical trial innovation rely stateoftheart choose basis oftheir pharmaceutical diagnostic genetic profilethis help research inhouse global collab reduce attrition rate ofcandidate orative network compound clinical develop menta pharmaceutical project key element close interplay evaluate early stage roche strategic nersgenentech californiausa theinterplay diagnostic chugai japanin hold therapeutic promote majority intereststhese company target use oftoday medicinesit large measure ofoperational contribute make new drug independence clearly define safe effectivethe food strategic framework genentech list drug administration fdafor new york stock exchange exampleha begin approve new chugai tokyo stock exchange drug labelling include genetic test informationand scientific commercial col announce plan new guideline laboration external company outline drug company university complement submit information medicine capabilitiesthrough alliance affect people differently depend strategic initiativesbiotech genetic makeuproche work ofroche main ing closely fda area strength help ofdiagnostic testsgreat roche division major progress predict research programme base minimisingside effectsand groundbreake discovery ice dosing far accurate land decode geneticsour alliance nowtodayfor examplean decode result average ofthe patient receiv identification ofa number ofgene ing medication derive immediate contribute common diseasesin sustain alleviation ofdisease examplegenetic risk factor symptomsquite apart prob heart attack osteoporosis lem ofdrugrelate adverse event discoveredin additionscientist new technology genechip decode pharmacogenomic enable understand effect clinical trial subsidiary encode gene mutation develop gene expression assay bodys response medicine predict responsiveness common treatment asthma hyperten sion high degree ofaccuracy group performance group strategyall ofthese project common goalto enable roche continue anticipate trendswe ahead industry trendsfor examplewhen webecame pioneer investor biotechnology stake genentechwhen acquire pcr andonce againwhen expand investment japanese health care market year agowe confident current portfolio ofresearch project alliance lead new breakthrough product service create value help ing provide solution unmet medical needswe intend remain true slogan innovate healthcare group performance group strategy edouard nonhodgkin lymphoma nhl common cancer lymphatic system today thank mabtherarituxan retire chemist able tend showcase garden mabtherarituxan combination chemotherapy therapeutic advance year improve survival patient aggressive form nhlpharmaceutical division brief change change local million chf currency chf sale sale roche worldwide prescription group nonprescription medicine otc ebitda operate profit research development employee exceptional item pharmaceutical successful year pharmaceutical division sale grow ahead world market fast rise operating profit thank strong performance division oncology portfolio especially mabtherarituxan roche extend numberone position important therapeutic areawe expect novel product like avastin help achieve strong leadership oncology future new hepatitis treatment pegasys surpass expectation year market term sale market penetrationanother milestone launch novel hivaids drug fuzeon nearly license agreement new technology product conclude complement strong internal research organisation pharmaceutical outstanding year ebitda total million swiss franc pharmaceutical divisionwe turn ofsalescompared pre impressive performance sale vious year cancer transplantation anemia prescription medicine prescription drug sale divisional sale medicine grow strongly pegasys exclude otc total million copegus surpass expectation swiss franc increase local currency launch fuzeon major market swiss francsoperating profit exceptional item reach mil william burns head pharmaceutical division lion swiss francsand operating profit marginat yearebitda increase million swiss francsor ofsale division oncology portfolio continue major contributor meeting commitment growth growthwith sale rise pharmaceutical division deliv million swiss francsle ere good performance sell productmabtherarituxan meeting commitment achieve launch ofpegasys copegus strong growth product sale new combination regimen profit hepatitis cmet early successsur pass expectation sale sale increase local curren market penetrationfuzeonour cie swiss franc novel hivaid therapyha million swiss francseven launch market worldwide newly integrate chugaisale grow cellcept neorecormon post fast global marketnew accelerate growthwith product establish roche product account experience doubledigit gain halfofsale growthoperate respective indicationssale profit exceptional item rise rocephin remain stable fast salesadvance early start ofthe flu season local currency swiss united statessales ofour flu drug franc million swiss franc tamiflu increase sharplyin line despite substantially high expendi expectation roaccutaneaccutane ture new drug launch experience sale erosion highly promising project generic competition development pipelinethe pharmaceu tical division post signifi oncology portfolio mabtherarituxan herceptin xeloda bondronat kytril furtulon increase profitabilityrecorde neupogen neorecormon roferona operating profit margin neutrogin picibanil exceptional itemscompare growth rate base local currency pharmaceuticalsabovemarket growth region pharmaceutical sale millions chf roche prescription medicine post abovemarket sale growth key regionsthank strong sale genentech rochesale north america increase signifi cantly outpace marketin europe prescription drug sale accelerate doubledigit rangethank pri marily good sale ofpegasysneo recormon oncology franchise strong sale increase record relatively sluggish japanese mar ket ascribe mainly con solidation ofchugai october aboveaverage underlie organic growtha result ofits alliance chugairoche rank fifth world secondlarg pharma ceutical marketin latin america roche numbertwo phar maceutical companysale return tomidsingle digit growth decline marketin rapidly develop market eastern europe china roche grow quickly strongly positioned indus ofallthey provide patient physi try leader cians new well therapeutic option pharma strategy leadership key therapeutic area innovation management leverage focus growth roche productivity improve focus key area ofhigh unmet med productivity ofthe great ical need core skill challenge currently face pharma competency difference ceutical industrydespite huge include oncologyvirology vance science technologyrd transplantation medicine anemia productivity stall ofour major goal leader andthe number ofapproval new area serve medicine fall roche believe future ofthe roche innovation strategy build pharmaceutical industry lie innova network link strong tionnovel drug prove medical house capability ofgenen benefit likely tech chugai independently approve regulator reimburse operating associate company healthcare payer important broad array oflicense alliance pharmaceutical gross sale sale deduct cash discount roche worldwide prescription group japan latin america sales region europe north america roche worldwide prescription group central nervous system infectious disease metabolic disorder cardiovascular disease dermatology inflammatory diseasesbone disease transplantation virology sale therapeutic area oncology anemia partner worldinnovation roche strengthen posi management essential tion world numberone oncol build current strong pharma ogy companywith billion ceutical pipeline swiss franc sale growth rate local currenciesour cancer ability structure agreement medicine remain large tailor interest need fast grow product portfolio party single currently account ofour pre producta technology entire scription drug saleswith portfolio result roughly new major oncology productsmabthera pharmaceutical alliance mak rituxanherceptin xelodaa e leader areain strong pipeline include avastin broaden ofour ongoing alliance tarcevaplus alliance develop enhance value party number ofadditional drug candidate include memory ipsen make important contribu alliancesour virology agreement tion improve survival quality withmedivirtrimeris stressgen oflife cancer patient number oftechnology research licence mabtherarituxan world therapeutic monoclonal antibody therapeutic area nonhodgkin lymphoma nhlone oncology cancer second ofthe common cancer ofthe common cause ofdeath indus lymphatic systemnhl affect approx trialise countrieseach yearmore imately million people worldwide million new case ofcancer claim estimate life diagnose worldwideand yearmabtherarituxan million cancer deathsin recent year inboth indolent aggressive major advance form ofnhl achieve sale drug treatment ofcancerand promi billion swiss franc e new approach develop indication contribute double mentthe global market cancer digitgrowth ofin september medicines forecast reach nearly mabtherarituxan approve billion swiss franc japan treatment ofaggressive billion swiss franc nhland national institute pharmaceuticalsa year world topranke women double player corina toface deadly new opponent learn rare form ofleukemia force toput career hold afterjust month chemotherapy hercancer remission enable enter open play benefit cancer research ace corina serve roche donate dollar friend cancer research washington clinical excellence nice herceptin monoclonal antibody united kingdom issue positive rec targeted treatment ommendation indication breast cancerthe common cancer clinical study show thatirre woman worldwidethe spective ofagepatient aggressive medicine tailor specific nhl treat mabtherarituxan patient subgroup herpositive combination standard chemo tumoursa genetically differentiate therapy improve chance aggressive tumour type account survival yearstrial datum approximately ofall breast announce december show cancersherceptin sale rise mabtherarituxan combination million swiss francsmake chemotherapy represent solid gain major marketsthe major clinical breakthrough increasingly widespread use ofher firstline treatment ofindolent lym test major growth driverfol phomathese datum expect lowing evidence combine use result expand indication ofherceptin taxol herposi potentially double number tive metastatic breast cancer patient ofpatient indolent nhl prolong lifea recent study simi benefit treatment larly show combination mabtherarituxana regulatory filing herceptin taxotere significantly combination submit improve patient survival compare authority january taxotere alonebase trial halt ear positive resultsroche file mar lier plan interim analysis keting application combination reveal primary efficacy end ofherceptin taxotere euro point reach pean unionwe expect approval pharmaceutical major product approval launch product generic indication country bondronat ibandronate prevention skeletal event patient breast cancer bone metastasis bonvivaboniva ibandronate treatment prevention postmenopausal osteoporosis usa switzerland fuzeon enfuvirtide treatment hiv usa switzerland invirase fortovase ritonavir saquinavir ritonavir ritonavirbooste regimen hivaids usa mabtherarituxan rituximab aggressive nonhodgkin lymphoma japan neorecormon epoetin beta week renal anemia pegasys peginterferon alfaa hepatitis japan raptiva efalizumab psoriasis usa renagel sevelamer hcl hyperphosphatemia japan valcyte valganciclovir prevention cytomegalovirus infection solid organ transplantation prevention cytomegalovirus infection kidney heart kidneypancrea transplantation usa xeloda capecitabine breast cancer japan xenical orlistat pediatric exclusivity usa xolair omalizumab asthma usa include supplemental indication update end january genentech chugai ongoing clinical develop theresult ofa largeongoe trial ment programme herceptin xeloda monotherapy adjuvant aim establish drug treatment ofpatient colorectal combination hormonal treatment cancer expect adjuvant set bondronat currently indicate xeloda sale continue strong management ofhypercalcemia upward trendgrowe abnormally elevate level ofcalcium united states sale ofthe product blood cancer patientsover advance tumouracti patient worldwide vate oral chemotherapeutic agent treat product datesale treat breast colorectal total million swiss franc cancerscolorectal cancer october bondronat gain common cancer man approval prevention ofskeletal womenin xeloda approve event pathological fracture bone treatment ofbreast cancer complication require radiotherapy japanroche conduct surgery patient breast pivotal trial xeloda different cancer bone metastasesthe new combination treatment ofcolo labelling reflect ability rectal breast cancer adjuvant bondronat significantly reduce metastatic settingsin addition metastatic bone painroche antici pharmaceuticalsjane totally focus swing long weigh memory terrible moment learn cancer return bad spread bone organ diagnostic test establish candidate treatment herceptin week start combination therapy show significant improvement today active australian feel fit healthy test result normal range pat strong uptake new indi andin key marketgermany cationwhich substantially increase sale double number ofpatient benefit drug potential effect chemotherapy neutropeniaan oncology supportive care roche abnormally low level ofwhite blood work way reduce cell play essential role effect complication ofcancer defend body bacterial therapyour supportive care product infectionsneutroginfor treat help alleviate suffer ofcancer ment ofthis conditioni oftwo patient significantly improve chugai product roche quality oflife group topselle prescription medicine achieve sale kytril potent antiemetic million swiss franc patient receive chemother apy radiation therapy anemia anemia occur undergone surgerythe product number ofre blood cell fall post steady sale growth andthank normalthus starve body ofoxy highly competitive profileis genit see ofpatient recapture market share fiercely impair renal function contest segmentin united states chronic kidney disease product clinic market share ofpatient cancerpotential increase longterm effect ofanemia cardio japan kytril vascular disease renal patient reinforce leadership position reduce survival patient increase market share cancer death ifit leave pharmaceutical topselle product roche worldwide prescription group change sale local product generic indication millions chf currency mabtherarituxan rituximab nonhodgkin lymphoma neorecormon epogin epoetin beta anemia rocephin ceftriaxone bacterial infection cellcept mycophenolate mofetil transplantation herceptin trastuzumab metastatic breast cancer pegasys copegus peginterferon alfaaribavirin hepatitis xenical orlistat weight loss weight control roaccutaneaccutane isotretinoin severe acne xeloda capecitabine colorectal breast cancer nutropin protropin somatropin somatrem growth hormone deficiency kytril granisetron nausea vomit induce chemotherapy radiation therapy follow surgery tamiflu oseltamivir treatment prevention influenza dilatrend carvedilol chronic heart failure hypertension coronary artery disease pulmozyme dornase alfadnase cystic fibrosis neutrogin lenograstim neutropenia associate chemotherapy cymevene valcyte ganciclovir valganciclovir cytomegalovirus infection activase tnkase alteplase tenecteplase myocardial infarction viracept nelfinavir mesylate hiv infection madopar levodopa benserazide parkinson disease lexotan bromazepam anxiety tension state jointly market roche genentech market chugai untreatedthe global market anti neorecormon achieve sale anemia product currently estimate million swiss francsan increase worth billion swiss franc ofthe use ofthis medicine oncology continue rise sharply roche neorecormon chugais successful product differentiation epogin lead product improve market penetration con treatment ofrenal anemia tribute impressive rise europe japanrespectivelycom sales segmenta marketing bin sale ofneorecormon application neweasytouse neo epogin show strong doubledigit recormon formulation onceweekly increase million swiss franc treatment ofanemic patient lym neorecormon achieve significant phoid malignancy recently sub market share gain europewhere mitte authority regulatory authority approve new regimen april dialysis roche ongoing commitment patient stable hemoglobin level improve anemia therapy lead pharmaceuticalswhen joyce teacher diagnose kidney failure lucky respect wait long asuitable donor organ akidney sister spare spend additional hour week dialysis machine prevent body reject new kidney joyce take immunosuppre sant medication therapy lifelong lowtoxicity cellcept amajor advantage development ofcera continuous immunosuppressant minimal erythropoiesis receptor activatoran toxicity like cellcept innovative compound currently test clinical trialsglobal filing roche immunosuppressive agent cerainclude submission cellcept topselling brand united statesare planned product united states pre venting organ rejectionwith sale transplantation transplantation totalling million swiss franc alifesaving measure people accelerate growth rate organ failureworldwidemore cellcept remain ofour solid organ trans important productsdata pre plant yearand number sente reaffirm product person live transplant safety efficacy showing organ estimate roughly unlike immunosuppre advance transplant surgery santstreatment cellcept parallel improvement increase risk ofcancer trans immunosuppressive therapy prevent plant patientssale ofzenapaxwhich organ rejectiona resultthe major combination cellcept ity oforgan recipient die ofother prevent acute kidney transplant cause fully functional tran rejectionshowe slight decrease plant time oftheir death accordinglycliniciansattention combine sale ofvalcyte cyme shift prevention ofacute rejec vene grow ofits tion avoidance oflongterm toxici potency simple dosing schedule tieswith use ofrelatively toxic valcyte increasingly medicine agent reduce favour choice prevent treating pharmaceutical cytomegalovirus infection egcmv hiv worldwide pan retinitisinitially approve use demicat end estimate hivinfected patient coinfecte million people live cmvthe product gain important hivaidsincluding million chil approval year european dren age ofwhile access union united states use basic medical care remain solid organ transplant patient press issue part ofthe cmv infection worldthe grow prevalence ofdrug resistant strain ofhiv pose con virology hepatitis virus hcv stant challenge pharmaceutical cause acute liver inflammation industry develop new therapeutic liver cancer leading reason optionsroche forefront liver transplantationmore effort combat hiv infection million people world aid commit dis infected hcvand mil cover develop innovative lion new case occur year new drug diagnostic test aid battle launch ofpegasys copegus mean roche offer new year fuzeonthe world combination treatment prove fusion inhibitorwa approve efficacy chronic hepatitis csale united states europe march reach million swiss mayrespectivelyfuzeon belong francsin month ofdecember new class ofantihiv treat pegasys account ment seven year total interferon prescription drug block virus hepatitis high enter host cellsthank new prescription diseasesale novel mechanism ofactionit offer ofthe combination therapy new hope patient devel drive high efficacysimple ope resistance antiretroviral convenient dose good tolerabil therapiesfuzeon available ity profilepegasys copegus countriesand important available treatment launch expect near hepatitis country futuresale total million october pegasys monotherapy swiss francsroche partner approve japancomplete reg trimeris actively work accel ulatory approval process major erate uptake offuzeon market worldwidelabelle change marketmajor physician patient approve summer european education initiative continue union result additional com ensure prescriber petitive advantagesunder new patient inform signifi labelling liver biopsy long clinical benefit fuzeon offer require start oftreatment manufacturing improvement duration dose ofcopegus increase production output ensure therapy base infect adequate supply viral genotype fuzeon pharmaceuticalsjame devastate learn hiv positive year live year ago meantime medical science achieve stunning breakthrough diagnosis treatment hivaid virus change develop ing resistance drug combat fuzeon truly innovative new hiv medicine seven year give james art lover live new hope time devote community project important protease inhibitor class patent enforce exist patent antihiv medicine pioneer right hivaid medicine rocheand mainstay world develop country ofmany hiv regimensnevertheless subsaharan africamoreoverroche combine sale ofour product supply protease inhibitor classviraceptinvirase fortovase country noprofit pricesfurther decline million information topic find swiss francsviracept remain sustainability report pressure competitor product wwwrochecom affect year additional price reduction important market primary care primary care contrastsale ofinvirase segment market product european union rise help xenicaldilatrend tamifluand approval ofa new regimen number ofinnovative medicine invirase ritonavir pipeline significantly grow recognition ofthe drugs effi strengthen position segment cacy safetythe regiman year approve united states decembernew dosage strength xenical remain leading viracept invirase help reduce weight management medicine number oftablet patient sale decline million daily product swiss franc line market trend competitive overweight obesity reach epidemic proportion united support global fight statesincreasinglyyoung people aidsroche decide file affectedcurrentlyabout pharmaceutical margaret contract hepa titis blood transfu sion disease go unnoticed year liver trans plant unavoidable specialist recommend clinical trial pegasys today trace virus leave blood thank pegasys healthy say active floridian good news grand child adolescent obeseand sale grow million overweightadolescent swiss francswell establish hyper obese great risk ofbee tension coronary heart disease obese adult ofdevelope seri dilatrend benefit late ous health problemsincluding type new positive clinical datum diabete heart diseasethey comet study confirm increase risk ofmortalityin drug confer significant survival december fda approve benefit patient chronic heart labelling use ofxenical manage failureroche expect sale decline ment ofobesity patient age dilatrend go yearsthe reimbursement landscape offpatent major european weight loss drug continue market begin ofapril challengehoweverpositive reimburse ment decision xenical sweden sale oftamiflu rise remarkable switzerland encourage million swiss continue effort areadata francsdue severe influenza publish december land break season mark xendos xenical japanwhere surveillance report indi prevent onset oftype diabete cate million people provide additional evidence infectedand early start favour ofreimbursement flu season unite stateswith million case dilatrenda lead beta blocking report farexpert expect agent hypertensionchronic heart equally severe outbreak japan failure coronary artery disease improve performance considerably pharmaceuticalsroche new bisphosphonatebonviva significantly enhance pharmaceuti boniva ibandronatewas approve cal development pipeline term bythe food drug administra ofquantityqualityand balance tion fda treat ment prevention ofosteoporosis pipeline currently postmenopausal woman receive strongwith new molecular entity apositive opinion use nmesinclude optin oppor indication european union tunitiesthe quality ofthe portfolio committee proprietary medicinal steadily improve past product cpmp octoberthe yearsand attrition rate product jointly develop latestage product fall rela glaxosmithklinethe aim tively low level period longterm treatment adherence easy terminate project patient postmenopausal phase phase total osteoporosis offer practical project terminate phase effective therapy condition include levovirin fusion base encouraging phase iii inhibitor tour project trial dataa supplemental filing balance different stage simplermore convenient dosage regi developmentwith project phase man submit project phase project inphase iiand project phase iii major product rocephin sale portfolio extend multiple remain stable early respiratory therapeutic areaseach ofwhich season united states compen target group major sated continue generic erosion europeespecially france ger continue drive create clinically manyfollowe expiry ofthe italian patent end ofdecember differentiate medicine expect european sale ofrocephin decline seamless process industry demand expect remain strong leadership build productive united stateswhere product continue protect patent strategic alliance bear fruit substantial portfolio new sale ofroaccutaneaccutaneroche innovative medicine today medicine severe acnefell million swiss franc good industry decline largely market jonathan knowles head global research entry ofcompete generics united states europe research development creative internal research devel opment alliance external innovator enable roche pharmaceutical growth areaand balance designate priority review term oflevel ofdevelopment riskwe fdaan filing submit currently research project december span seven therapeutic area development project thera tarceva cancer medicine design peutic area interfere molecular signal stimulate tumour cell growth key development project solid tumourstwo phase iii move ahead plannedwe achieve study patient nonsmall cell important clinical advance phase lung cancer meet primary highly promising project endpointa monotherapy trial cera anemia mabthera tarceva pretreate lung cancer rituxan mra rheumatoid patient proceed plannedwith arthritis eligible enter result expect quarter phase iiiwe expect report roche continue clinical phase product development oftarcevaas drug useful treat variety oncology result phase iii cancer trial latestage cancer drug avastin show increase sur joint programme develop new vival duration patient receive oncology product kosanipsen avastin plus chemotherapy firstline antisoma progress track treatment metastatic colorectal canceravastin monoclonal anti anemia development ofour inno body design block vascular vative anemia treatment cera growth factor critical worldwide use anemic patient development ofnew blood vesselsa cancer renal disease move ahead process know angiogenesisangio plannedresults phase genesis essential growth clinical study show cera solid tumour metastatic highly effective dialysis patient spreadinterrupte process chronic renal anaemiafurthermore potentially stop slow tumour result phase iii study show growth starve exist tumour cera effective treating anemia tissue shrinkavastin rep multiple myeloma cancer patient resent promise new approach phase iii study renal patient treatment ofcancerwith broad schedule start early potential use number ofsolid phase iii trial cancer patient tumoursand useful com start end ofthe year plement conventional chemother apyroche genentech jointly transplantation profile ofthe novel develop product commer immunosuppressant isa post cialise genentech united transplant patient continue stateschugai japan roche additionroche inlicense drug countriesan application candidate potential use trans approval ofavastin file plantation rheumatoid arthritis united states september cardioncurrently preclinical pharmaceuticalsdelif ecnalab dna ytilauq ytitnauq smret enilepip decnahne noitacidni iii esahp esahp esahp esahp noisnetxe enil rojam eman cireneg epyt tcudorptcejorp aera cituepareht aimena detaler recnac dna aimena laner tnemtaert aimena noitareneg txen aimena aimena tnemtaert aimena sesaesid yrotammalfni ydobitna lanolconom enobnoitammalfni esaesid lewob yrotammalfni tsinogatna nirgetni sitirhtra diotamuehr rotibihni esanik sitirhtra diotamuehr rotibihni esanik sitirhtra diotamuehr tsinogatna nirgetni siroropoetso noitneverp dna tnemtaert tanordnabi etanohpsohpsib avinobavivnobr yliad sisoropoetso noitneverp dna tnemtaert nettimretni dna laro ylhtnom sitirhtra diotamuehr bamixutir ydobitna lanolconom naxutirarehtbam sitirhtra diotamuehr ydobitna lanolconom armr setebaid epyt rotaludom rotpecer raelcun msilobatem ytisebo rotaludom rcpg setebaid epyt rotibihni emyzne setebaid epyt rotaludom emyzne setebaid epyt rotibihni emyzne setebaid epyt rotaludom rotpecer raelcun setebaid epyt rezitisne nilusni bnapaj tnempoleve tatsilro rotibihni esapil lacinex stnemdnema lebal esaesid sremiehzla rotaludom rcpg metsys suovren noisserpe rotaludom rcpg esaesid sremiehzla rotibihni emyzne esaesid sremiehzla rotibihni emyzne esaesid sremiehzla rotibihni emyzne yteixna dna noisserpe rotaludom rcpg yteixna dna noisserpe rotaludom rcpg sromut dilos rotibihni emyzne ygolocno sromut lacigolotameh ygolocno ydobitna lanolconom recnac nairavo bamomutmep ydobitna lanolconom recnac tsaerb ydobitna lanolconom sruomut dilo enolihtope rotibihni emyzne sruomut dilos rotibihni emyzne sruomut dilos rotibihni emyzne sruomut dilos bamuzutrep ydobitna lanolconom gratinmor sruomut dilos nacetomolfid rotibihni emyzne sruomut dilos rotibihni emyzne nbr sruomut dilo binitolre rotibihni esanik avecratr seitivitca tnempoleved tnioj bamuzutsart ydobitna lanolconom nitpecreh recnac tsaerb tnemtaert tnavujda aimekuel citycohpmyl cinorhc bamixutir ydobitna lanolconom naxutirarehtbam enil tslhn tnelodni noitanibmoc citatsatem dna tnavujda enibaticepac adolex recnac noloc tnemtaert recnac tsaerb tnavujda recnac latceroloc citatsatem enil bamuzicaveb ydobitna fgevitna rnitsava noitanibmoc sromut dilo rehto dna yparehtomehc htiw esaesid yranomlup evitcurtsbo cinorhc rotibihni emyzne yrotaripser amhtsa tsinogatna nirgetni amesyhpme tsinoga rotpecer raelcun noitcejer tnalpsnart laner etuca rotibihni nirueniclac tnalpsnart ecnenitnocni yraniru ssert rotaludom rcpg ygoloru noitcnufsyd elitcere elam tsinoga rcpg ecnenitnocni yraniru dexim dna ssert rotaludom rcpg sititapeh rotibihni esaremylop ygoloriv telbat wen rivaniuqas rotibihni esaetorp esarivni sititapeh cinorhc aafla norefretnigep norefretni detalygep sysagep noitalumrof wen esaesid vih etalysem rivaniflen rotibihni esaetorp tpecariv noitcefni lairetcab citoibitna sesaesid suoitcefni chcetneneg hguorht noitapicitrap sitirhtracitairosp bamuzilafe ydobitna adcitna milenax ylremrof avitpar bafuhr sitnecul noitarenege ralucam detalerega tnemgarf ydobitna lanolconom baf dma ylremrof ciaguhc hguorht noitapicitrap amoleym elpitlum ydobitna lanoloconom mha sisoropoetso enomroh dioryhtarap tnanibmocer shc recnac tsaerb lxtetamatulgylop chc sesatsatem enob ydobitna lanoloconom lac sisoropoetso evitavire nimativ esaesid traeh yranoroc tnadixoitna siseraportsag tsinoga nilitom ymotcetapeh tsop rotareger revil lav egahrromeah dionhcarabus savetna nemow lasuaponemtsop recnac tsaerb elozortel aramef nemow lasuaponemtsop sisoropoetso lch enefixolar atsive dseitinutroppo nitpo emordny yranoroc etuca stnemgarf ydobitna lanolconom bafft hcetneneg ydobitna nlm esaesid lewob yrotammalfni ydobitna lanolconom pdl yllamrof gnilaeh dnuow rotcaf htworg lailehtodne ralucsav fgev noitcefni lagnuf lagnufitna lab lagnufitna aelisab noitcefni lairetcab citoibitna lab citoibitna esrever edisoelcunnon rividem esaesidvih rotibihni esatpircsnart setebaid epyt mib nespi sruomut dilos tnega gnittegrat ralucsav aaxmd amositna era eseht enilepip tnempoleve snoisivid slacituecamrahp eht semn yltnerruc era ereht sesaesid yrotammalfni rednu detsil srentrap lanretxe esahp era gnitset lacinilc esahp deretne evah esahp tnempoleve egatsylraeni ygolocno rednu dna sesaesid enob nespi secneic nohpyrg iii esahp dna ton yam stcejorp emos snosaer evititepmoc rofb isohcetneneg hcetneneg deifitnedi neeb evah akinhcetosi enilkhtimsoxalg tnempoleve lacinilc lacinilcerp morf noitisnart esahp noitadilosnoc llufc rezifpnorugua cedihcetneneg stneitap ylbissop dna sreetnulov yhtlaeh seiduts laitini esahp tcudorp eht esnecil thgir eht sniater ehcord oyknas iaguhc stneitap seidut gnidnifesod dna ytilibarelot ycaciffe esahp sitravon slacituecamrahp yromem ycaciffe dna ytefas noitamrifnoc lacitsitat rof stneitap seidut elacsegral iii esahp seititne ralucelom wen stneserper epyteulb yllil ile amositna semn secneicsoib nasok rebmece tnerructestingthe compound expect research project help roche consolidate position major therapeutic area december key medical area virology pegasys fulfil pro metabolic disorder virology mise potent antiviral therapy oncology vascular disease inhcv patient normal alt whoare consider mild urogenital disease hepatitis routinely con inflammatory disease sidere treatmentpegasys demon central nervous system strate excellent result reduce viral loadoffere potentially curative treatmentresult autoimmune disease autoimmune largescale global trial ofhepatitis disease occur immune sys patient coinfecte hiv tem attack bodys cell available foreign microorganismsmore clinically distinct autoimmune trial phase iii disease identifiedeach pegasys hepatitis confirm affect body different way superior standard rheumatoid arthritis rafor exam medicine currently prescribe pleis characterise joint inflam diseasethese findingsalong data mation whichdespite treatmentcan hepatitis trialswill form result progressive joint destruction basis filing pegasy treat ultimately lead loss offunction ment hepatitis ofthe affect jointsthe cause billion people worldwide thisautoimmune disorder unknown infect hepatitis virus hbv nearly million people suffer approximately million people raworldwide chronic hbv infectionsan esti mate million people die year rochegenentech idec devel hepatitis complication ope mabtherarituxan treat ment ofrathe efficacy safety roche trimeris decide datum proofofconcept proceed clinical development trial drug good ofthe potential antihiv medicine give combination ofdifficultie achiev drugsmabtherarituxan ing technical profile require promise substantial sustained current formulationin january improvements treatment outcome company underscore represent entirely new ongoing commitment improve approach treatment ofra hiv care signing research agree roche biopharmaceutical ment develop new generation develop mrathis fusion inhibitorsthe new agreement roche codevelopment project focus investigation ofimprove chugaivery positive datum formulation delivery technology european phase study pre peptide fusion inhibitor sente year major international pharmaceutical roche consumer health know congresses united states europephase iii testing ofmra build strong brand year way japan brand help create value halfof slate start year united states euro roche group business pean union competitively advantage grow roche aspreva pharmaceuticals fast marketwe intend form unique alliance develop cellcept use continue develop brand autoimmune diseasesin additionthe commercial alliance roche position strength protein design labs pdl richard laube head roche consumer health restructure allow pdl develop zenapax indication transplantation primary care current phase pipeline include potential medicine stress urinary incontinencedepre sion prophylaxis chronic treatment ofasthma lead otc brand change type diabetes disease recog sale local product use million chf currency nise global pandemic ofenor aleve naproxen analgesic mous magnitude create supradyn multivitamin comprehensive portfolioincluding bepanthen skin care insulin sensitiser rcurrently rennie antacid phase development redoxon vitamin nonprescription medicine otc sale ofnonprescription roche consumer health product medicinesinclude sale chugai japangrew local currency swiss franc million swiss franc skin hair care analgesic roche consumer health rch gastrointestinal product achieve strong organic growth sale therapeutic area exclude chugaisale increase local currency million vitamin swiss francssubstantial sale growth report marketsbut especially asiapacific region eastern europethe topsell ing brand post robust growth pharmaceuticalsdemonstrate rch excellent pharmaceutical division remains brandbuilde capabilitiesbepan commit achieve operate thenredoxon aleve profit margin approach main growth driverschugais otc beforeexceptional item end sale line expectation ofthis equivalent previ ously announce goal ofan adjust operating profit otc busi margin approach ness total million swiss franc exceptional itemsa gain local currency swiss franc previous yearthe operating profit margin decrease slightly low profitability chugais otc business invest ment develop xenical orlistat otc product outlook base achievement pharmaceutical division solid mediumterm perspectivewith sale expect grow fast world market anticipate continue strong growthfor cancer productsthe addition ofavastin oncology portfolio major milestone set stage continu e leadership oncology sector anticipate increase sale pegasys andfuzeon expect neo recormonepogin cellcept remain major sale driversrocephin roaccutaneaccutane expect play important role overall portfolio thank current future productswe ideally position sustained growth core area competencyoncologyvirology anemiawe expect maintain current strength specialty care sector pharmaceutical thank treatment pegasys margaret live miami completely clear hepatitis infec tion viral load monitor reliable highly sensitive molecular diagnostic test blood virus free patient viral disease roche effort align diagnosis treatment response monitor vitally important pcrbase blood test enable doctor determine stage patient disease help guide decision dose duration therapydiagnostic division brief change change local million chf currency chf sale sale diabetes care near patient testing centralized diagnostic molecular diagnostic apply science ebitda operate profit research development employee exceptional item diagnostic major acquisition disetronic insulin pump igen immuno chemistry strategic alliance affymetrix dna chip continue aboveaverage sale gain combine successful year roche diagnostic despite limited global market growth division maintain global leadership fact increase preeminence competition grow market share post substantial doubledigit increase profitability diagnostic provision information generate large number attractive new productswith clinical decision base play new product launch roche increase role healthcare diagnostic demonstrate capacity innovation market future global aboveaverage growth worldwide market leader aim successful division record significant sale area assay gain regionsdespite weak negative growth world major system diagnostic market heino von prondzynski head diagnostic division sale north america double market averagein europe market characterise healthcare budget restrictionssale growth sale japan rise compare despite decline market asa wholein asiapacific iberialatin america roche diagnos global market lead extend tic expand market share sale diagnostic division doubledigit sale growth total million swiss francsa yearonyear increase diagnostic strategy local currency swiss help shape diagnostic francsroche diagnostic grow market future roche twice fast global invitro theonly diagnostic company diagnostic market supply market segmentsfrom research scientist right profitability measure continue consumersto maintain fasterthan improveoperating profit average growthwe pioneer exceptional item local development new area currencie million swiss promise significant medical benefit francswith ebitda rise local currency million swiss aim consolidate leadership francsthe operating profit margin inthe invitro diagnostic market percentage point focus highvalue growth area ebitda margin advance diabetesmolecular diagnostic percentage point immunochemistry expand ing health information market division profitable fastestgrowe business area dia innovation management building bete care molecular diagnostic strength develop new market immunochemistry product promote development ofnew main contributor market maintain technology strong performancefurther growth lead futurewe pursue diagnosticsthreepronge strategystrengthen diagnostic sale millions chf inhouse research development pursue acquisition alliance lead technology companiesand promote internal venture accordinglywe invest financial human resource research development competitor result innovative power demonstrate fact gen erate ofsale product launch yearsin alonethe diagnostic division file patent application immunochemistry product line annually growth area ofmolecular diag nostic build exist signing licensing agreement portfolio expand oncology affymetrixwe take challenge pharmacogenomicsfocuse ofbuilde market dna chip diagnostic product support early clinical diagnostic scratch diagnosisdisease prevention tar amplichip cypa test pro get treatment vide information individual metabolic variation affect action acquisition alliance complement ofcertain widely drug differ strength access ent patientsis product additional innovative technology result alliancethe test help acquisition ofdisetronic avoid adverse drug effect cause strengthen lead incorrect dosage represent diabete segmentby combine pioneer achievement road blood glucose measurement individualised therapeuticswhich insulin pump technologyroche set replace present drug fit able offer integrate diabete allapproachanother key alliance management solutionsthe acquisi formedwith epigenomicsaim tion ofigenwhich expect identify new cancer marker complete mid february give roche unrestricted access division internal venture process immunochemistry sectorvalue enter yearthis billion swiss francsimmuno initiative give employee oppor chemistry big segment tunity implement new business theinvitro diagnostic marketthis idea incompany startups strategic acquisition place usin currentlyten ventures operating anideal position market japannorth america europe leader segment medium venture strategically long termin year important health information sector wehave increase sale ofour elecsy solid market presence diagnostic gross sale sale deduct cash discountsbusiness area improvement diabete man diabete care diabete care grow agement rely integration local currenciesoutpace separate market substantial margin technology blood glucose meas consolidated lead posi urement insulin delivery tion blood glucose monitoring aim ofcreate artificial pancrea asiapacific japan near patient testing apply science molecular diagnostic europe sale region sale business area north america diabetes care centralize diagnostic iberialatin america million people suffer acquisition ofdisetronicthe diabetesand world health world secondlarg supplier organization estimate insulin pumpsis important figure rise million strategic moveas result ofthis regularaccurate blood glucose transactionwhich finalise monitoring help prevent compli roche offer compre cation cardiovascular disease hensive range ofproduct people reduce followon costsroche diabetesfrom glucose monitor diagnostic play major role e anddata management insulin inshape trend glucose self delivery monitor portable glucose meter accurate clinical integration ofdisetronic inter laboratory national site proceed accord plan com roche diabetes care expand plete countriesroche optimise portfolio ofblood work closely fda glucose monitor systemsnew ver address agency concern sion oftheproven accuchek advan disetronic production process tage accuchek active glucose documentationwe intend resume meter post good sale right pump sale second startas new test strip halfofreinspection fda accuchek compactthe new strip expect place give fast result blood middle ofthe yearthe burgdorfsite successfully pass european additionthe rollout ofaccuchek technischer berwachungsverein goa novelparticularly userfriendly audit end glucose meterstarte end diagnosticsyi sheng retire diagnose diabete today passion eat amateur painter shanghai know people diabete lead fectly normal life sim ply learn disease control thank builtin con venience accucheck advantage monitor blood glucose level come nat urally sheng simple brushstroke near patient testing near patient clear market leaderwith market testing lead supplier ofprod share uct service rapid pointof care diagnosis patientshome hospital point ofcare segment doctorsofficesambulance inten rapid diagnostic product use sive care unitstotal sale decrease accident scene intensive care local currency unit roche steadily improve streamline ofthe product range market sharekey factor early year divestment ofthe high growth segment opti system drugsofabuse test decision refocus activity e businesseson comparable basis core business strong sale sale near patient testing rise ofcardiac assay omni blood gas local currency analysersas result ofthe outbreak ofsevere acute respiratory syndrome worldwide sale ofcoagulation moni sar begin tore product grow order blood gas analyser china demand fuel mainly time plan continue trend patient selfmoni production output market toringthe medical economic worldwide yearwe advantage ofselfmonitore prove ability meet increase document international demand crisis real clinical trialsresulting decision contribution save live increase number ofeuropean health insurer reimburse cost new multifunctional omni coagulation monitor blood gas analyserlaunched segment roche diagnostic mayis way diagnostic topselle product line change sale local product line market segment business area millions chf currency accuchek glucotrend diabetes management diabetes care cobas integra roche hitachi clinical chemistry centralize diagnostic elecsys immunochemistry centralize diagnostic amplicor test cobas amplicor molecular clinical diagnostic molecular diagnostic cobas ampliscreen molecular blood screen molecular diagnostic coaguchek coagulation monitoring near patient testing exclude hia homogeneous immunoassay toduplicate strong sale modular analytic swa formance ofomni ishighthis trend reflect growth ofcentralize diagnostic information management steadily significantly outperform gain importancein futurecom themarket sale local puterbase system significantly currency accelerate enhance medical diag nosticsthis demonstrate againthe elecsys immunochem astudy ofdatacare poc conduct istry product line post doubledigit inthe netherlands gainswe constantly expand show software help hospi system test menu add tal achieve substantial time cost new hormone marker assay new saving therapeutic drug monitor drug concentration test primary care segment compact system doctorsoffice multi market response elecsys parameter systems ofthe reflotron probnpa highly innovativefully product line accutrend cholesterol automate test diagnose chronic testing product post aboveaverage heart failure monitor patient growththe rollout ofa new genera response treatmentcontinue tion ofinstrument offer standard bevery positiveit available ise urinalysis meet good market europe united statesand response application marketing approval file japanin novem centralized diagnostic workflow ber fda additionally clear elec efficiency crucial laboratory diag sys probnp test risk stratifica nosticswhere cost pressure major tion chronic heart failure acute factorlarge laboratory hospital coronary syndromemake need powerfulintegratedcosteffec assay simultaneously cover tive laboratory systemsaccordingly applicationschronic heart demand modular hightech system failure common disease western diagnosticscountrie high mortality business segmentin rateearly diagnosis deci business area demonstrate capac sive impact progression ity develop innovative invitro diag nostics substantial increase transfer hema local currency salesa expect tology business partner sale ofenzyme industrial cus sysmexthis allow company tomerswhich account relatively focus core competency small percentage ofrevenuesdecline increase profitabilityall agreement sysmex outside unaf sale growth ofblood screening test fecte test sexually transmit dis ease high doubledigit expect complete acquisition rangealong test hivaid ofusbase igenannounce july hepatitisthese product contin mid february ued key sale driver strategic secure right use ofelectrochemiluminescence molecular diagnosticssuccess base ecl technology allow polymerase chain reaction pcr totap new market technologywhose development thedivision large growth area substantially pioneer roche immunochemistrywhich account pcrsegment ofdna ofthe invitro diagnostic amplify million market surpass dia copiesmake possible diagnose bete monitor roche diag disease rapidly reliably nostic intend systematically expand market share seg roche diagnostic successfully mentthe acquisition ofigen give meet major challengesfirstin roche new nonexclusive right week develop permit fully exploit potential pcrbase test detect virus ofecl technology develop cause sarsa previously unknown elecsys product line respiratory diseasedevelopment thetestwhich research use acquisition announce onlywa possible roche centralized diagnostic goodcollaboration receive large ordersincluding thegenome institute ofsingapore laboratory chain bioscentia research organisationssecond schottdorfone inrecord time molecular diagnostic europe large commercial laborato develop highly automate riesin additionin sign test detect west nile virus number ofmajor multiyear contract donate bloodthe testwhich include hospital detect pathogen belong organisation amerinet japanese encephalitis virus group introduce united states molecular diagnostic mar canada clinical trial mid ket share ofover roche molecu identify unit lar diagnostic unrivalle leader ofcontaminate donor blood diagnostic major approval product launch business area product diabete care test strip accuchek compact blood glucose meter accuchek advantagesensor blood glucose meter new version accuchek blood glucose monitoring system accuchek active blood glucose meter new version near patient testing omni multifunctional blood gas analyser diavant internetbased service urisys urinalysis system datacare poc centralise data instrument management software omnilink blood gas analyser management software centralize diagnostic elecsys shbg hormone assay therapeutic drug monitoring test amikacin lidocain quinidine elecsys probnp assay heart disease new indication molecular diagnostic amplichip cyp microarray drug metabolism research use cobas taqman realtime pcr analyser amplicor hpv human papilloma virus test reagent lightcycler factor factor tests thrombosis risk assessment clinical use lightcycler sar assay research use taqscreen west nile virus test clinical trial apply science lightcycler dna amplification system magna pure compact nucleic acid purification system lighttyper instrument snp analysis prionic check lia test bse madcow disease june see launchfor research cobas taqman launch useofamplichip cypthe worlds united states june receive pharmacogenomic microarray marketing approval shortly infuture new dna chipbase test system put realtime pcr tech help physician select appro nology reach ofsmall priate medication dosageroche mediumsize laboratory work obtain approval timegive roche access new cus united states europe clinical tomer segmentsthe improve tech diagnostic version ofthe test nology offer significant advantage include fast resultshigher sensitiv end united states ity wide measurement range roche launch reagent enable moreoverroche protect qualitative testing ofthe clinically realtime pcr technology relevant subtype ofhuman patent worldwidethe european papilloma virus hpvthe lead launch ofthe large cobas taqman cause ofcervical cancerinitiallythe incombination cobas reagent isavailable use certain ampliprep sample preparation instru specialist diagnostic laboratory mentis schedule second roche plan launch clinical diag quarter expect nostic version early stimulate growth diagnosticsa decision european patent research development adjustable penetration depth office uphold roche year diagnostic division great user comfort patent taq dna polymerase repeatedly demonstrate inno akeycomponent ofpcr technology vative strength area diabete near patient testing emer bring close lengthy dispute care pcrbase diagnostic gency physician need fast access patentability ofthis enzyme test result information risk europea court action addition longterm develop factor directly actionable health united states concern patent ment plan new system test informationthis require innovative isstill pende roche diagnostic able solution instrument respond quickly emerge medical clearly define parameter menusour apply science provider need marketoriente solution mediumterm goal include reagent hightech system sci demonstrate important test single platform entific industrial researchapplied development record time ofnew form ofmodular desktop science come pressure test sar west nile virus handheld deviceswe plan sluggish economic climate strengthen cardiac marker weak biotech marketespecially roche diagnostic invest portfolio heartfailure test unite statesconsequently million swiss franc forthecardiac reader system sale decline local currency research development newdevelopment howeverthank establish rep utation partner life science diabetes care roche diabetes care schedule launch research worldwide follow focus development ofan improve test strip clear realignment genomics comprehensive solutionssuch inte coaguchek coagulation monitor proteomic begin grated spot monitor system glu product line ofa new pointof roche apply science cose meter combine test strips care datum management application equip future automatic check ofstrip integrity web functionality lancing system link innovative product launch insulin delivery system sophis centralized diagnostic centralize use genomic deserve ticate information systemsin addi diagnostic focus complete solu special mentionan update version tionwe continue work tion help diagnostic laboratory lightcycler offer great versatil develop glucose measurement tech increase productivity reduce ity research applicationsmagna nique require blood costsroche work steadily pure compacta compact benchtop sample toexpand systemst menus instrument fasteasy nucleic launch ofnew marker treatment acidpurificationthe new lighttyper enhance version ofour accu monitor osteoporosis skin snp analysis snpsor single chek pocket compass diabete man cancer ofa combine hiv antigen nucleotide polymorphismsare small agement softwarewhich antibody assay plan variation indna asso compatible insulin pump largely unexplored ciate certain diseasesfinally isslated launch addi field ofproteomic conduct prionic check liaa newfully auto tiona new generation ofinsulin research innovative marker mate test enable detection pump schedule launch condition asrheumatoid arthri bseor madcow diseasein slaugh second halfyearother key project tis colorectal cancer tere cattlereceive marketing plan launch approval europe new lancing systemsoneconsid molecular diagnostic molecular ere worldwide hygiene diagnostic systematically expand safetyfrom accuchek softclix ing pcr product portfolioblood product linethe new model screeningnow secondbigg diagnostic mountain bike doris get life move right direc tion mother dori get heart valve operation fine absolutely vital monitor anti coagulant therapy little drop blood take coaguchek provide information need need selfmonitore help peo ple stay independent market pcr application currently available virologycontinue gain impor research use certain specialist tancecurrent project area laboratoriesthese include amplichip include fully automate system cyp hpv reagent screen donor blood product infectious pathogen apply science year inadditionwe develop new business area successfully serve market womens healthmicro need ofresearch laboratory biologygenomicspharmacogenomic worldwidefollowe expansion oncology area refocus genetic pro teomicsapplie science continue pursue joint project meet high expectation ofit affymetrixdecode epigenomics customersthe development ofscien develop clinical diagnostic test tific service key focus base pcr genechip technol come yearsalong continue ogydiscover gene variant identify development ofthe lightcycler tech new tumour markersrespectivelyfol nology platform expand range lowing amplichip cypwe intend ofapplication increase sample commercialise dna chipbase test throughputhighthroughputcycler range ofdiseasesespecially realtime pcr analyser schedule oncologywe expect ofthese forlaunch prod microarray available research uctin additionwe develop use month aninnovative system rapid pro duction ofcustomisable dna chip plan launch clinical lifescience research diagnostic version ofseveral product diagnosticskey product launch schedule business area product diabetes care safe tpro plus lance system accuchek softclix lance system accuchek pocket compass diabete management software minitron insulin pump new generation near patient testing coaguchek pt test strip coagulation testing datacare web pointofcare datum management software centralize diagnostic elecsys pnp bone formation marker treatment monitor osteoporosis elecsys treatment monitoring skin cancer sta cephascreen coagulation test hiv combi combine hiv antigen antibody assay urisys urinalysis system molecular diagnostic amplichip cyp microarray drug metabolism clinical use lineararray hcv test hepatitis virus genotype lineararray hpv test human papilloma virus clinical use integrate cobas ampliprep cobas taqman system sample preparation dnarna analysis lightcycler instrument dnarna analysis clinical diagnostic version lightcycler hsv iii test herpe simplex virus clinical use apply science multiple reagent use genomics research lighttyper system snp analysis magna pure system nucleic acid purification isolation outlook roche diagnosticsrecent strategic move disetronicigen affymetrix mean position develop new product market high growth potential help ofdna microarray cuttingedge technology aim advance paradigm shift individualised healthcare solution play lead role develop market health information roche diagnostic track achieve objective ofabovemarket growth fiscal operat ingprofit margin exceptional item ofaround equivalent previously announce goal ofan adjust marginof diagnostic corporate governance roche group commit stakeholder strive serve diverse interest customer employee shareholder holder roche non vote equity security balance fashion commitment reflect operate businessesfocus value creation management culture conform modern standard corporate governance group policy communicate transparently organisational structure committee presidium board director chair independent director roche board ofdirector organ ise ensure group bylaw ofthe board ofdirector business conduct responsibly contain detail internal focus longterm value structure ofthe boardthe allocation creationthereforesome year ago ofauthority responsibilitiesthe board ofdirector ofroche holding mandate ofthe board committees ltd delegate certain responsibility information control committeesthese commit mechanism available board tee dealing corporate manage presidium ofthe board mentare publish internet directorsnomination committee audit corporate governance article committee thebylaw ofthe board ofdirector finance investment committee wwwrochecom company corporate remuneration committee governance board bylaw ccoorrppoorraattee ggoovveerrnnaanncceeremuneration member executive committee number number fix salary fix salary bonus bonus option option chf chf chf chf award award humer altwegg burn hunziker keller jkc knowle laube von prondzynski villiger total employee option issue roche pro rata period october december avicechairman ofthe board remuneration member atthe request ofany memberconvene executive committee board meeting attend member ofthe executive ance ofthe chairmanin futuresuch committee receive salary meeting convene vice bonus stock option show chairman name independent table remuneration ofmember lead director board ofdirec ofthe executive committeeand torsonce year roche board additionally receive bearer meet assess chairman perfor share mention late section mance absencethis meeting chair future inde pendent lead director option grant entitle holder purchase roche non remuneration voting equity security genussschein remuneration member price swiss francsunder board director term ofthis longstanding option member ofthe board ofdirector planthe exercise price closing receive annual remuneration price roche nonvoting equity swiss franc serve board security trading day remuneration pay chairman roche annual media conferencethe ofthe board service option nontradable capacity deduct agree exercise later february salarymember serve board com onethird ofthese option mittee receive additional compensation subject vest period ofone year swiss franc time onethird vest period oftwo expensesremuneration compen yearsand onethird vest period sation pay nonexecutive member ofthree yearsunvested option lapse ofthe board ofdirector serve compensation ifa member aforementioned capacity total voluntarily leave companywhile million swiss franc vested option exercise corporate governance limited period oftimeifthey december onethird ofthe tradabletheir fair value option award holder date ofissue exercisable exercise value roughly swiss franc option swiss franc optiona base blackschole formula december option deduct aver exercise member ofthe age twoyear vest period executive committee option grant entitle event attend member holder purchase roche executive committee nonvoting equity security price key manager swiss francsthe option roche groupeach attendee nontradable exercise receive roche bearer share later february onethird time market value ofthese option subject vest swiss franc ing period ofone yearonethird vest period oftwo yearsand director member ofthe execu vest period ofthree year tive committee receive annual expense unvested option lapse com allowance swiss pensation ifa member voluntarily francsrespectivelythe chairman leave companywhile vested board receive annual expense option exercise allowance swiss francsin alimited period oftimeifthey member ofthe executive tradabletheir fair value date committee receive expense ofissue allowance total swiss swiss franc option base franc onthe blackschole formula average vest period oftwo year time ofhis retirement markus altwegg award special bonus indirect benefit million swiss franc recogni ahvivalv tion ofover year ofservice pension fundsmgb roche connect chf chf companyincluding year humer member ofthe executive committee altwegg bonus pay burn hunziker indirect benefit keller employer contribution jkc knowle social security laube schemespension plan group von prondzynski wide employee equityshare plan villiger roche connect respect ofmem total ber ofthe executive committee show table indirect benefit ahvivalv swiss social security programme provide retirement disability unemployment benefit mgb stiftung der fhoffmannla roche agfr mitarbeitergewinnbeteiligung employee profit roche connecta voluntary sharing foundation supplement occupational pension benefit equity purchase planemployee corporate governancethe opportunity buy roche non stock option vote equity security rogis market value total value original award option dec issue price equal oftheir annual number dec chf chf award chf salary discountnonvote humer equity security purchase altwegg plan subject hold period burn switzerlandfor exampleis keller year jkc knowle von prondzynski stock option villiger december member total executive committee hold option tradable option purchase nonvoting equity security issue party issue dis award previous year show tribute april security identification exercise price swiss franc exercise inthe table stock option ratio expiry date april vest period end april original issue price swiss franc taxable value recipient issue date swiss franc december nonexec utive member ofthe board ofdirec tor hold unvested option award ment security issue peer set previous year company operate industryparticipate executive performance share plan award fix number ofnon member ofthe executive com voting equity security mittee member oftop board discretion cash equiva management performance lend end ofthe effective period major impact roche ability ofthe planperformance evalu achieve corporate objective ate basis ofmarket price individual worldwide partici dividend yieldsifan investment pat performance share plan roche security outperform establish begin peer setthe board ofdirector ofifover period elect increase number programme effectan invest nonvoting equity security award ment roche security share twofoldin event nonvoting equity security outper investment roche security form average return invest perform average return deliver peer companiesfewer performance share plan nonvoting equity security awardedunder provision ofthis number ne target plan programme nonvoting equity securi humer tie reserve member burns executive committee set hunziker table belowthe programme keller effect period ofthree year jkc knowle number ofnonvote laube equity securities reserve gottlieb von prondzynski akeller increase total ofhis increase responsibili corporate governance tie newly appoint member pension total swiss franc executive committeethe number pay executive ofsecuritie reserve partici committee member widow pant plan remain unchanged addition benefit board ofdirector vote receive pension plan actual distribution ofsecuritie plan close ofthe otherwiseno additional remunera financial reporting year tion pay current member ofthe board ofdirector remuneration emolument current member ofthe loan corporate officer executive committee daniel villiger step executive committee high total remuneration requesthis remuneration chairman ofthe board ceo year detailed table franz bhumer member hecease member ofthe roche board member ofthe pension fund december executive committee highest receive portable benefit enti total remuneration show tlement provide fund table ruleswith respect option award award performance shareholding share planthe arrangement director andr hoffmannandreas drvilliger accord provi oeri fritz gerber members sion ofthe applicable planshencethe ofthe founder family closely table include award associate belong share villiger entitle holder group pool voting right exercise end group hold share ofissue markus altwegg gottlieb akeller sharesmr gerber leave group take mortgage loan retire board swiss franc april detailed information respectivelywith pension fund group foundin note fhoffmannla roche ltdat inter roche group consolidate est rate pathe interest rate financial statement relate party loan fix decem note ber financial statement ofroche hold ltd additiona fritz gerberwho serve roche december nonexecutive ceo chair member ofthe board ofdirector man ofthe roche board andperson closely associate todoe receive benefit hold sharesthe member fromany ofthe roche pension fund ofthe executive committee receipt ofan annual son closely associate hold pension company share date pension total swiss franc corporate governancerelationship group auditor additional information relate financial statement ofroche statutory auditor corporate governance hold ltd additional group auditor statutory auditor group structure shareholder detail contain article participate audit corporate roche operate business ofincorporation ofroche hold governance committee meeting organise divisionsphar ltdwhich find auditor write oral report maceutical diagnosticsthe internet wwwrochecom result oftheir auditsthe audit pharmaceutical division comprise change equity detailed corporate governance committee business segment roche note financial statement oversee assess auditor prescriptiongenentech prescrip ofroche hold ltd make recommendation board tionchugai prescription roche change occur consumer healththe diagnostic reader refer group auditorspricewaterhouse division consist offive business roche annual report cooper agreceive follow areasdiabetes carenear patient company share capital remuneration service testingcentralize diagnostic swiss francsdivide molecular diagnostic apply fully pay bearer millions chf sciencebusiness activity car share nominal value auditing service rie group subsidiary swiss franc eachthere lim auditing group safety associate companiesthe itation transfer ofthese environmental protection report important subsidiary associ share share maximum auditrelated service ate company list note voting rightsupon depositshare tax consultancy service consolidate financial state vote restric consulting service ment subsidiary associate tion total companiespage addition nonvoting major shareholder list note equity security issue ernst young ltd receive follow roche group consolidated bearer formthey form e remuneration service financial statement relate ofthe share capital statutory auditor ofroche hold party note confer voting rightseach non ltd roche financial compa financial statement vote equity security confer ny auditor ofgenentech rocheholding ltd right share partici chugai andr hoffmannandreas oeri pate available earning fritz gerber serve board liquidation proceed follow chf director representative ofthe repayment ofthe share capital roche audits shareholder pool voting roche nonvoting equity security auditrelate service roche right receive remuneration provision secure genentech chugai audits mention remuneration claim right pertain thereto consulting service member ofthe board ofdirector describe ofthe article provide genentech abovedr gerber additionally incorporation ofroche hold ltd chugai receive aforementioned pen information debt instrument total sionno relationship exist issue shareholder pool standing bond find group auditor statutory auditor vote right note roche group elect year annual crossholding consolidate financial statement general meeting debt capital structure information roche capital wwwrochecom company corporate structure provide note governance article incorporation corporate governance additional information employee science ethic advisory stock option find note group seag issue relate roche group consolidated genetics genetic engineer financial statement employee ing establish stock option equity year board ofdirector compensation benefit impose blackout period roche issue option apart senior employee award prohibit trading com employee issue connection pany stockthe follow blackout debt instrument period effect option award january february employee debt instrument april april issue july july effect roches share capital october october blackout period change board director executive chairman ofthe board ofdirec committee tor ifcircumstance warrant information member ofthe board ofdirector hold total board ofdirector executive offive meeting committee include year management contract elect fall meaning year term end subsection ofthe swx direc list page curriculum tive information relate vitae information corporate governance board executive committee member available participatory right shareholder wwwrochecom participatory right ofshare internal organisation ofthe holder define roche arti board ofdirector division cle ofincorporationa roche ofauthority responsibility share issue bearerthere board management restriction admission govern bylawsthis annual general meetingswith document publish inter exception share net wwwrochecom deposit specify period board ofdirector estab date ofa meeting lishe system ofcontrol admittance card issue overseen corporate govern shareholder namea provide ance committee consist ofthe ofthe article ofincorpora follow element tionany shareholder elect report financial operating represent shareholder risk internal audits wwwrochecom company corporate compliance officer governance wwwrochecom company corporate safety environment officer governance board bylaw corporate sustainability com wwwrochecom company corporate mittee governance article incorporation corporate governanceat annual general meetingthe relevant information visor report com article ofincorporation contain documentsinclude pliance officer andrea greuterdirect restriction exercise ofvote medium release presentation phone number rightsand quorum require analyst investor conference disclosure treat ment stipulate areavailable english german confidentialemployee ofthe article ofincor internet wwwrochecom disclosure penalise porationshareholder represent publication order company sobut share nominal value ofat emailfax telephone arenot immune prosecution swiss franc baselwebmasterrochecom forlegal violation request placement ofitem tel business agenda ofan annual fax gottlieb kellerwho serve general meetingthis contact address investor group compliance officer later day date relation step post ofthe meeting fhoffmannla roche ltdinvestor end ofhis new duty relationscorporate finance member ofthe executive commit change control defensive baselswitzerland teethe board ofdirector name measure tel andreas greuter succeed keller article ofincorporation con fax compliance officermr greuter tain provision mandatory additional informationincluding report directly chairman bid ruleswiss law apply detail specific contact person theboard ofdirector submit change ofcontrol isavailable wwwrochecom regular report audit clausesthose component ofremu corporate governance committee neration base roche nonvoting nonapplicabilitynegative equity security termi disclosure nate event ofan acquisition expressly note informa vest period restriction tion contain mention preexisting award nonapplicable omission removedso option construe negative disclosure immediately exercise compliance officer information policy compliance officer commit provide ofthe article ensure roche corporate prin incorporationcorporate notice ciple consistently comply publish schweizerische roche group handelsamtsblatt daily serve contact person share newspaper designate board holdersemployeescustomerssuppli ofdirector basler zeitungfinanz ers general public issue und wirtschaftlagefile temp relate implementation ofand neue zrcher zeitung compliance principle roche report halfyear consistent provision year result business report pub intent ofthe sarbane oxley act lishe print online format section employee medium conferencesin addi party aware ofviola tionfirst thirdquarter sale tion ofroche corporate principle figure publish year bring april october attention oftheir manager super wwwrochecom investor corporate governance finance roche finance significant progress provide solid platform value creation entrepreneurial develop ment group achieve condition balance financial income end debt reduce billion swiss franc instrument cover convertible debt obligation refinancedand shortterm bank debt replace attractive longterm financing furthermore reduce risk expo sure financial investment foreign exchange transaction core business pharma diagnostic continue achieve improved operating result strong cash generationa result group net liquidity increase billion swiss franc billion swiss franc ratio equity minority interest total asset improve financefinancial review highlight millions chf roche group continue businessesa change change local local cur cur chf rency chf rency sale ebitdab operating profit exceptional item operating profit net income continue business include core pharmaceutical diagnostic business treasury corporate activity vitamin fine chemical division report discontinue business ebitda earning exceptional item interest financial income tax depreciation amor tisation include impairment correspond operate profit exceptional item depreciation amortisation include impairment operate roche group continue business pharmaceutical diagnostic show steady progress local currency sale core business roughly organic growth remainder acquisition chugai growth local currency operating profit exceptional item drive sale growth particularly high margin product business area reduce operating expense operating cost increase chugai integration launch expense high research develop excellent cash generation pharmaceutical diagnostic show ebitda billion swiss franc actively support effort condition place balanced financial income end end roche group show significantly improve key financial figure take additional step improve transparency investor erich hunziker chief financial officer financial review ment expense high administration cost take account exceptional item local operating profit growth strong mainly result income million swiss franc genentech legal settlement second half compare charge genentech legal case city hope medical center strength swiss franc relative currency particular dollar thejapanese yen negative impact result example dollar worth chf average compare chf result increase theoperate profit exceptional item group continue business translate intoa increase swiss franc term result discontinue vitamin fine chemical business sell dsm effective september include group result month group operating profit include vitamin fine chemical increase billion swiss franc billion swiss franc increase driver positive result core business partially offset impact div ment vitamin fine chemical business notably impairment charge million swiss franc loss divestment million swiss franc result include million swiss franc expense vitamin case million swiss franc vitamin fine chemical business impairment treasury finance significant progress achieve condition balance financial income end roche show improve financial strength step take include restructure reduction group debt refinance instrument cover convertible debt obligation reduction financial risk exposure achievement principally base strong cash generation operate business major item like proceed sale vitamin fine chemical business dsm addition debt significantly reduce bank loan switch capital market debt bullet lyon debt instrument repay total cash outflow billion swiss franc conversion helveticus bond reduce debt million swiss franc issue european medium term note programme raise proceed billion swiss franc attractive condition refinance exist shortterm bank debt longterm capital market financing group net liquidity increase billion swiss franc billion swiss franc group reassess refinance instrument cover potential conversion obligation arise convertible debt instrument december group reclassify forward purchase nonvoting equity security equity debt thiswas base development international accounting lyons convertible bond redeem freedup nonvoting equity security cover potential conversion obligation partly disetronic acquisition partly sell proceed close forward purchase potential conversion obligation lyon sumo convertible bond cover low exercise price option future cash commitment classify equity debt result transaction group strong transparent balance sheet close forward purchase reduce interest expense longterm debt december longterm debt reduce billion swiss franc financial longterm asset reduce billion swiss franc net cash outflow billion swiss franc additional detail give note consolidated financial statement financial reviewthe financial risk exposure decrease proportion financial asset heldin equity reduce net adverse effect net income equity security billion swiss franc total cash marketable security compare billion swiss franc end total cash marketable security market risk financial asset measure valueatrisk var model indicate confidence month potential loss asset value exceed million swiss franc impairment charge financial asset million swiss franc million swiss franc arise share experience large fall second half fail recover sufficiently follow month group impairment threshold impairment second half million swiss franc foreign exchange risk reduce profit continuously increasingly lockedin favourable movement exchange rate reduce foreign exchange transaction exposure accord valueatrisk analysis confidence potential foreign exchange loss month exceed million swiss franc roche show significantly improve balance sheet healthy risk profile operating result continue business exceptional item millions chf sale core business sale grow local currency swiss franc roche group record sale billion swiss franc core business represent increase local currency swiss franc approximately increase organic growth integration ofchugai growth drive pharmaceutical division rate sale growth increase significantly reach local currency swiss franc thediagnostics division post increase local currency swiss franc change change local chf currency pharmaceutical total prescription roche prescriptiona genentech prescription chugai prescriptionb otcc diagnostic sale continue business sale exclude nippon roche prescription classify chugai prescription segment sale consist chugai prescription nippon roche prescription consist roche otc chugai otc financial review operate profit substantial growth profitability increase operate profit exceptional item continue business exclude result vitamin fine chemical division increase local currency swiss franc billion swiss franc growth drive increase sale low operating expense development partially offset increase operating cost primarily result chugai integration investment market new product pegasys fuzeon activity support development pipeline newly inlicense andoptin compound operate profit exceptional item margin increase percentage point percent sale change change local chf currency sale cost sale gross profit marketing distribution research development administration amortisation intangible asset operating income operating expense operate profit continue business exceptional item gross profit increase swiss franc billion swiss franc compare gross profit margin remain stable reflect strong growth inhighmargin prescription product effect continue productivity improvement compensate low average gross profit margin chugai disetronic acquisition accounting integration impact marketing distribution increase swiss franc billion swiss franc increase drive support newly launch product pegasys copegus fuzeon geographic rollout prelaunch launch activity genen tech xolair raptiva avastin chugai renagel xeloda pegasys group level acquisition chugai contribute local growth marketing distribution percentage sale remain fairly stable research development increase swiss franc billion swiss franc tosupport strong research development pipeline pharmaceutical diagnostic include inlicense optin compound group level acquisition chugai con tribute roughly local growth research development cost percentage sale group level reach level valid pharmaceutical account group research development expense reach sale diagnostic reach financial reviewadministration increase swiss franc billion swiss franc group level acquisition chugai contribute local growth remainder primarily drive genentech acquisition disetronic amortisation intangible asset increase swiss franc billion swiss franc amortisation intangible asset chugai acquisition million swiss franc compare million swiss franc fourth quarter dise tronic million swiss franc operating income increase swiss franc billion swiss franc pri marily second half gain million swiss franc disposal neupogen compensate second half gain million swiss franc million dollar sale protein design labs exclusive worldwide right market develop sell zenapax disease indication organ transplantation half litigation settlement income bayer operating expense decrease swiss franc billion swiss franc reduction primarily million swiss franc low foreign exchange loss receivables latin america turkey recovery correspond currency million swiss franc low restructuring expense million swiss franc low sap implementation cost low impairment charge partially offset high royalty expense divisional result continue business exceptional item millions chf operate operating profit ebitda profit exceptional sale exceptional item party ebitda sale item sale pharmaceutical total prescription roche prescription genentech prescription chugai prescription otc diagnostic group total continue business financial review operate operate profit ebitda profit exceptional sale exceptional item party ebitda sale item sale pharmaceutical total prescription roche prescription genentech prescription chugai prescription otc diagnostic group total continue business pharmaceutical sale pharmaceutical division reach billion swiss franc increase local currency swiss franc ebitda total billion swiss franc inlocal currency swiss franc margin remain fairly stable sale operating profit exceptional item increase local currency swiss franc billion swiss franc margin rise high operating profitability drive sale growth spite considerably increase spend new product schedule launch support exist product particularly neorecormon strong research development pipeline operat ing income operating expense decline parallel income gain sale zenapax right protein design lab partially compensate gain onneupogen expense decline particular absence restructuring expense million swiss franc million swiss franc impairment charge relate tothe pharmaceutical division restructure low foreign exchange loss receivables inlatin america turkey total prescription local currency sale prescription medicine rise billion swiss franc swiss franc growth drive roche successful oncology product product contribute strong sale growth include pegasyscopegus neorecormon cellcept sale antibiotic rocephin remain stable continued high demand italy growth compensate generic competition europe particular france germany acne medicine roaccutaneaccutane decline local term tighter prescription requirement generic competition europe xeni cal sale decrease line market trend roche prescription business improve operating profit exceptional item percent sale percentage point increase gross profit margin low operating expense increase gross profit margin partially result additional manufacturing validation start scaleup cost pegasys fuzeon increase regulatory compliance cost low operating expense primarily significantly low foreign exchange loss receivables cost relate pharmaceutical division restructure positive effect partially offset increase marketing effort newly launch product pegasyscopegus fuzeon increase cost strong research development pipeline genentech prescription business continue strong sale profit growth ebitda margin increase primarily result increase sale financial reviewat high gross profit margin economy scale production milestone payment research collaboration partner ebitda margin genentech prescription business underline strong contribution group operate cash generation chugai prescription business post operating profit exceptional item million swiss franc ebitda margin compare development drive high sale improve gross profit margin positive effect chugais restructuring programme combine effect million swiss franc final writeoff remain fair value adjustment inventory result acquisition accounting million swiss franc restructuring expense record roughly level writeoff fair value adjustment inventory million swiss franc otc sale nonprescription medicine rise local currency swiss franc billion swiss franc roche consumer health sale exclude chugai grow local currency billion swiss franc strong growth market especially asiapacific eastern europe drive bepanthen redoxon aleve otc operating profit exceptional item total million swiss franc grow local currency swiss franc compare operate profit exceptional itemsmargin decline percentage point sale decline drive thelower profitability chugais otc business investment develop orlistat xenical asan otc product diagnostic sale increase local currency swiss franc twice fast theworldwide market invitro diagnostic billion swiss franc growth drive profitable business area diabetes care invitro diagnostic business molecular diagnostic immunodiagnostic business centralize diagnostic downturn biotech research negatively impact growth rate apply science divestment ofthe nonclinical drugofabusetesting business opti product line negatively impact growth rate near patient testing diagnostic level sale growth impact divestment offset acquisition disetronic exceptional item oper ate profit increase local currency swiss franc billion swiss franc ebitda swiss franc billion swiss franc profitability improve operating profit ebitda margin percentage point sale respectively high marketing spend rise research development expense forthe broad research development pipeline industry high amor tisation intangible asset result disetronic acquisition offset reduce sap implementation cost gain continue product portfolio asset realignment litigation settlement income bayer result consist cost corporate headquarters discontinuing operation million chf sale operating profit exceptional item vitamin fine chemical business effective september receive final regulatory approval group complete sale global vitamin fine chemical business dutch company dsm result roche group include result vitamin fine chemical business september financial review exceptional item millions chf continue business discontinue business group operating profit exceptional item amortisation goodwill major legal case change group organisation operate profit amortisation goodwill remain stable billion swiss franc increase inlocal currency goodwill amortisation chugai acquisition accounting million swiss franc compare million swiss franc addition million swiss franc goodwill amortisation disetronic acquisition follow implementation recent accounting change company accounting princi ple generally accept united states gaap long amortise goodwill require perform impairment test annually roche continue amortise goodwill include hold genentech require international financial reporting standard ifrs present exceptional item view propose ifrs change improve comparability healthcare peer major legal case million swiss franc income cash receive million swiss franc litigation settlement genentech second half year net expense million swiss franc result judgement igen litigation issue july million swiss franc provision record genentech legal case city hope medical center change group organisation net proceed receive dsm billion euro billion swiss franc include provisional deduction agree price adjust ment mechanism mainly relate cashanddebtfree basis work capital level vitamin fine chemical business final amount arise mechanism include net debt calculation subject review approval group dsm andare liable change take account incidental transaction cost residual obligation retain roche group preliminary assessment september show additional loss disposal million swiss franc arise disposal vitamin fine chemical business addition impair ment charge million swiss franc record half final assessment follow review approval group dsm income million swiss franc recognise chugai transaction impairment charge million swiss franc record vitamin fine chemical business operating profit major impact exceptional item operate profit continue business increase local currency swiss franc billion swiss franc high growth compare growth local currency swiss franc operating profit exceptional item mainly result oneoff income million swiss franc genentech legal settlement second half compare charge genentech legal case city hope medical center financial reviewincome associated company million chf continue business discontinue business group income associate company result associate significant major impact come basilea financial income million chf continue business discontinue business group financial income exceptional impairment financial asset financial income decrease net expense million swiss franc net income million swiss franc comparative result include gain million swiss franc labcorp transaction exclude gain financial income anet expense million swiss franc net income equity security loss million swiss franc result include impairment charge million mainly relate equity security december market value group impairment threshold sustained sixmonth period exclude impairment charge income million swissfranc achieve equity security interest income million swiss franc adecrease relative prior year cause low holding debt security fall interest rate interest expense reduce million swiss franc mainly reduction restructure debt fall interest rate impact interest rate large part debt fix group achieve net foreign exchange gain million swiss franc profit continuously increasingly lockedin favourable movement exchange rate breakdown financial income give note consolidated financial statement income taxis millions chf continue business discontinue business group profit taxis income taxis profit taxis group continue business effective tax rate remain stable year despite increase profit contribution genentech chugai high tax rate group overall effective tax rate tax effect vitamin fine chemi cal disposal group effective tax rate continue business exceptional item reconciliation tax charge give note consolidated financial statement financial review minority interest millions chf continue business discontinue business group minority interest income applicable minority increase mainly continually improve profit contribu tion genentech impact genentech legal case cause swing million swiss franc million swiss franc income applicable minority relate genentech million swiss franc relate chugai net income million chf continue business discontinue business group net income earning share nonvoting equity security basic chf diluted chf group return profit large exceptional charge incur netincome include year chugai group net income include month result vitamin fine chemical business additional impairment net asset loss disposal cash flow net liquidity million chf cash flow statement cash generate business operation net cash inflow outflow major legal case operate cash flow operating activity income taxis income taxis pay activity operating activity financing activity invest activity net effect currency translation cash increase decrease cash financial reviewoperate cash flow group operation continue strong cash generation business operation billion swiss franc drive continued growth ebitda cash flow operating activity improve greatly compare period low vitamin case payment inclusion billion swiss franc payment collateral account relation igen litigation reverse net inflow billion swiss franc low net cash outflow income taxis large income tax receivables record end recover tax authority finance cash flow significant financing cash flow dividend payment billion swiss franc billion swiss franc repayment bullet bond lyon note billion swiss franc proceed issue group european medium term note programme refinance exist shortterm debt refinance instrument cover convertible debt obligation result cash outflow billion swiss franc note consolidated financial statement invest cash flowsthe significant cash flow proceed billion swiss franc divestment vitamin fine chemical business consist billion swiss franc receive dsm net billion swiss franc cash hold divested company invest cash flow include increase expenditure property plant equipment intangible asset net cash outflow group portfolio marketable security order fund purchase disetronic debt repayment vitamin case payment net liquidity december december cash marketable security financial longterm asset derivative financial instrument net equity instrument financial asset longterm debt shortterm debt total debt net liquidity net liquidity increase outflow dividend payment acquisition ofdisetronic cover strong cash flow operating activity fund receive divestment vitamin fine chemical business financial review debt instrument transaction affect debt cash net effect lyon iii lyon note total book value billion swiss franc reclassify shortterm longterm debt redeemable option group january respectively balance sheet millions chf december december change longterm asset current asset total asset equity minority interest noncurrent liability current liability total equity minority interest liabilitie longterm asset sale vitamin fine chemical business reduce property plant equipment billion swiss franc billion swiss franc collateral account relation igen litigation repay group lower financial longterm asset theacquisition disetronic increase goodwill intangible asset billion swiss franc financial longterm asset reduce billion swiss franc collateral support instrument cover convertible debt obligation release current asset sale vitamin fine chemical business impact current asset notably reduce inventory billion swiss franc equity significant movement net income billion swiss franc billion swiss franc dividend payment minority interest increase drive improve performance genentech cur rency translation effect noncurrent liability proceed european medium term note programme increase longterm debt billion swiss franc lyon iii lyon notes book value billion swiss franc classify shortterm debt refinanc ing instrument cover convertible debt obligation reduce longterm debt billion swiss franc current liability repayment bullet bond lyon note decrease short term debt billion swiss franc vitamin case payment billion swiss franc reduce shortterm provision reclassification lyon iii lyon notes book value billion swiss franc increase current liability financial reviewfinancial risk foreign exchange risk group operate world expose movement foreign currency affect net income financial position express swiss franc local local currency currency chf chf growth continue business sale operating profit exceptional item december average december average exchange rate swiss franc usd eur gbp jpy average swiss franc strong dollar japanese yen weak euro total negative currency effect sale growth continue business operate profit growth point absolute term sensitivity group sale continue business change dollar swiss franc swiss franc average approximately million swiss franc correspond sensitivity euro yen approximately million swiss franc million swiss franc respectively group monitor net currency exposure appropriate enter transaction aim preserve value asset commitment anticipate transaction group use forward contract swap foreign currency option optimise certain anticipate foreign exchange revenue cash flow financing transaction group pursue astrategy continuously lockin favourable development foreign exchange rate enter derivative contract reduce exposure potential future move foreign exchange rate result group overall transaction risk decrease continuously transaction risk monetary position quantify valueatrisk var approach measure potential negative impact foreign exchange result adverse change inforeign exchange rate var calculation base normal market condi tion confidence level hold period day december december foreign exchange risk millions chf change var monetary position interest rate risk interest rate risk arise movement interest rate adverse effect thegroup net income financial position change interest rate cause variation interest income expense interestbeare asset liability addition affect market value certain financial asset liability instrument group manage interest rate risk necessary financial derivative swap option financial review group pursue goal reduce debt consequence exposure potential change interest rate decrease continuously interest rate var measure thepotential change net market value interest rate sensitive asset liability con tinuously decline potential increase interest expense movement interest rate material group major debt instrument fix interest rate group level potential impact interest rate change financial instrument monitor quan tifie valueatrisk var earningsatrisk ear model var measure potential change fair value interest sensitive financial instrument ear reflect potential change net annual interest expense result adverse interest rate movement var ear measure historical simulation approach normal market condition aconfidence level hold period day december december interest rate risk millions chf change var instrument sensitive interest rate ear instrument sensitive interest rate market risk financial asset change market value cash marketable security affect net income financial position group market risk arise movement stock price interest rate foreign exchange rate group decide change risk profile reduce equity position considerably equity security billion swiss franc billion swiss franc total cash marketable security continuous shift group asset allocation result reduction var year market risk measure valueatrisk var model base confidence level hold period day exclude position genentech chugai run treasury operation independently var represents expect level loss exceed probability follow day december december market risk financial asset millions chf change var cash marketable security valueatrisk earningsatrisk analysis tool valueatrisk var calculation indicate range value respective asset liability fluctuate certain probability certain time period hold period var measure statistical measure implicitly assume value change recent past indicative value change future market shock include calculation recently observe group conduct additional stress test ing possibility consideration group use statistically relevant observation period apply hold period reflect time period require change respec tive risk exposure deem appropriate long hold period probability high value change increase var measure financial reviewearningsatrisk ear equivalent var methodology potential value change indicate potential change profit loss certain probability acertain time period constraint limitation apply methodology var ear model base historical simulation approach simulate effect historical price rate movement current position historical scenario represent price rate change individual instrument specific day period past financial instrument fully revalue valuation model total change value earning determined group predict future market movement var ear figure give notrepresent actual loss expect incur financial asset liability possible bad loss period state consider effect favourable change market rate financial review roche group consolidated financial statement reference number indicate corresponding note consolidated financial statement consolidated income statement million chf continue discontinuing business business group sale cost sale gross profit marketing distribution research development administration amortisation intangible asset operating income operating expense operate profit exceptional item amortisation goodwill major legal case change group organisation operate profit income associate company financial income profit taxis income taxis profit taxis minority interest net income earning share nonvoting equity security basic chf diluted chf roche group consolidated financial statementsconsolidate income statement millions chf continue discontinuing business business group sale cost sale gross profit marketing distribution research development administration amortisation intangible asset operating income operating expense operate profit exceptional item amortisation goodwill major legal case change group organisation operate profit income associate company financial income exceptional impairment financial asset profit taxis income taxis profit taxis minority interest net income earning share nonvoting equity security basic chf diluted chf sale marketing distribution expense reduce million swiss franc reclassification cash discount note roche group consolidate financial statement consolidate balance sheet million chf december december longterm asset property plant equipment goodwill intangible asset investment associate company financial longterm asset defer income tax asset longterm asset total longterm asset current asset inventory account receivable current income tax asset current asset marketable security cash cash equivalent total current asset total asset equity share capital nonvoting equity security genussscheine equity instrument retain earning fair value reserve total equity minority interest noncurrent liability longterm debt defer income tax liability liabilitie postemployment benefit provision noncurrent liability total noncurrent liability current liability shortterm debt current income tax liability provision account payable accrue current liability total current liability total equity minority interest liability pro memoria nonvoting equity securities nominal value note roche group consolidated financial statementsconsolidate statement change equity million chf year end december share capital balance january december nonvoting equity security genussscheine balance january december equity instruments balance january acquisition disetronic conversion helveticus bond refinance instrument cover convertible debt obligation movement year reclassification obligation repurchase equity instrument balance december retain earning balance january net income dividend pay balance december fair value reserve balance january increase decrease fair value income expense recognise income statement defer income taxis minority interest currency translation gain loss balance december total equity december pro memoria nonvoting equity securities nominal value note roche group consolidate financial statement consolidated cash flow statement million chf year end december cash flow operating activity cash generate operation increase decrease work capital vitamin case payment igen litigation genentech legal case payment define benefit postemployment plan restructure cost pay utilisation provision operate cash flow cash flow operating activity income taxis pay income taxis pay total cash flow operating activity cash flow financing activity proceed issue longterm debt instrument repayment longterm debt instrument increase decrease longterm debt refinance instrument cover convertible debt obligation transaction equity instrument increase decrease shortterm borrowing interest dividend pay genentech chugai stock repurchase exercise employee stock option genentech finance cash flow total cash flow financing activity cash flow invest activity purchase property plant equipment purchase intangible asset disposal property plant equipment disposal intangible asset disposal product acquisition subsidiary associate company divestment subsidiary associate company proceed sale labcorp share interest dividend receive sale purchase marketable security net invest cash flow total cash flow invest activity net effect currency translation cash increase decrease cash cash equivalent cash cash equivalent begin year cash cash equivalent end year consist cash cash equivalent roche group consolidated financial statementsnote roche group consolidated financial statement reference number indicate corresponding note consolidated financial statement summary significant accounting policy basis preparation consolidate financial statement consolidate financial statement roche group prepare accordance international financial reporting standard ifrs include standard interpretation issue international accounting standard board iasb prepare historical cost convention disclose accounting policy certain item include derivative availableforsale investment show fair value approve issue board director february preparation consolidated financial statement require management estimate assumption affect report amount revenue expense asset liability disclosure contingent liability date financial statement future estimate assumption base management good judgement date financial statement deviate actual circumstance original estimate assumption modify appropriate year circumstance change necessary comparative reclassify extend previously report result account presentational change group change presentation income statement financial statement current year comparative result split continue discontinuing business impairment longterm asset cost pharmaceutical division restructuring classify operating expense amortisation goodwill intangible asset present separately operate income operat ing expense income associate company present profit taxis order well comparability result healthcare company allow reader clear assessment sustainable earning capacity group result reclassify new format operate profit netincome earning share unchanged previously report result consolidation policy financial statement consolidate financial statement roche holding ltd acompany register switzerland subsidiary group subsidiary company control directly indirectly roche holding ltd control define power govern financial operating policy enter prise obtain benefit activity control normally evidence roche holding ltd own directly indirectly vote right potential vot ing right company share capital special purpose entity consolidate sub stance relationship special purpose entity control group company acquire year consolidated date operating control transfer group subsidiary divest include date control pass note roche group consolidate financial statement group company acquire exclusively resold near future consoli date classified asset hold sale carry fair value intercompany balance transaction result unrealised income eliminate investment associate company account equity method com panie group exercise significant influence control isnormally evidence group own voting right potential voting right company balance transaction associate company result realise income eliminate extent group interest associate company interest joint venture report linebyline proportionate consolidation method segment report group primary format segment report business segment secondary format geographical segment risk return group operation primarily deter mine different product group produce geographical location group operation reflect group divisional management organisational structure group internal financial reporting system group division pharmaceutical diagnostic disposal september group division vitamin fine chemical pharmaceutical division subdivision roche prescription genentech prescription chugai pre scription consumer health otc subdivision separate management reporting structure pharmaceutical division consider separately reportable segment certain corporate activity reasonably allocate reportable segment cost corporate headquarters report thegroup geographical segment determine geographical location similarity economic envi ronment transfer price business segment set arm length basis divisional asset liability consist property plant equipment goodwill intangible asset trade receivablespayable inventory segment asset liability consist asset liability reasonably attribute report business segment include pension assetsliabilitie provision nonsegment asset liability mainly include current defer income tax balance financial asset liability principally cash marketable security investment debt capital expenditure com prise addition goodwill intangible asset addition property plant equipment include arise acquisition foreign currency translation group company use local currency measurement currency certain group company use currency dollar swiss franc euros measurement currency usefully represent result financial position com panie give local economic condition circumstance local transaction curren cie initially report exchange rate date transaction gain loss settlement transaction gain loss translation monetary asset liability denominate currency include income qualify cash flow hedge defer equity note roche group consolidated financial statementsupon consolidation asset liability group company measurement currency swiss franc foreign entity translate swiss franc yearend rate exchange sale cost expense net income cash flow translate average rate exchange year translation difference change exchange rate begin end year difference net income translate average yearend exchange rate take directly equity divestment foreign entity identify cumulative currency translation difference relate foreign entity recognise income gain loss divestment revenue cost sale sale represent amount receive receivable good supply customer deduct trade discount cash discount volume rebate exclude sale value add taxis revenue sale product recognise transfer customer significant risk reward usually shipment revenue record earn service perform cost sale include correspond direct production cost relate production overhead good manufacture service render startup cost vali dation achievement normal production capacity expense incur royalty income recognise accrual basis accordance economic substance agreement report operate income research development research cost charge income incur development cost capitalise intangible asset probable future economic benefit flow group intangible asset amortise straightline basis period expect benefit review impairment balance sheet date development cost charge income incur criterion recognition asset met inlicense milestone upfront receipt payment certain group company notably genentech receive thirdpartie upfront milestone similar nonrefundable payment relate sale licensing product technology revenue associate performance milestone recognise base achievement milestone define respective agreement revenue nonrefundable upfront pay ment licence fee initially report deferred income recognise income earn period development collaboration manufacturing obligation pay ment group company party associate company item charge income research development cost probable future eco nomic benefit flow group normally evidence regulatory approval case capitalise development cost amortise describe practice mean inlicense milestone payment pharmaceutical product expense incur case gain regulatory approval receipt pay ment consolidate subsidiary genentech chugai roche group subsidiary eliminate consolidation extent impact minority interest note roche group consolidated financial statement employee benefit wage salary social security contribution pay annual leave sick leave bonus nonmonetary benefit accrue year associate service render employee group group provide longterm employee benefit cost accrue match rendering service employee concerned group operate number define benefit define contribution plan world cost year define benefit plan determine project unit credit method reflect service render employee date valuation incorporate actuarial assumption primarily discount rate determine present value benefit project rate remuneration growth longterm expect rate return plan asset discount rate base market yield highquality corporate bond country concern difference assumption actual experience effect change actuarial assumption allocate estimate average remain work live employee difference exceed define corridor past service cost allocate average period benefit vested pension asset liability different define benefit scheme offset group legally enforceable right use surplus plan settle obligation plan pension asset recognise extent group able derive future economic benefit way ofrefund plan reduction future contribution group contribution define contribution plan charge income statement year relate group operate equity compensation plan include separate plan genentech chugai fix plan roche option plan equivalent plan genen tech chugai expense recognise date issue exercise price greater equal fair value underlie equity instrument date issue subsequent cash flow exercise vest grant record equity case genentech chugai plan balance sheet minority interest performance relate variable plan roche performance share plan stock appreciation right expense accrue vest period difference exercise price fair value ofthe underlie equity instrument group disclose value issue option blackschole option valuation model blackschole model develop trade option vest transfer restriction plan group include restriction fair value option issue lower unadjusted value imply blackschole methodology taxation income taxis include taxis base taxable profit group include withhold taxis payable distribution retain earning group taxis base onincome property capital taxis include operating expense financial income accord nature provision income taxis mainly withhold taxis arise remittance retain earning principally relate subsidiary current inten tion remit earning note roche group consolidate financial statementsdeferred income taxis provide liability method temporary difference tax basis asset liability carry amount financial statement defer income tax asset relate carryforward unused tax loss recognise extent probable future taxable profit available unused tax loss utilise current defer income tax asset liability offset income taxis levy taxation authority legally enforceable right offset deferred income taxis determine base currently enact tax rate applicable tax jurisdiction group operate property plant equipment property plant equipment initially record cost purchase construction depreciate straightline basis land depreciate estimate useful life major class depreciable asset follow building land improvement year machinery equipment year office equipment year motor vehicle year investment grant similar assistance project initially record deferred income inoth noncurrent liability subsequently recognise income useful life relate asset repair maintenance cost recognise expense incur borrowing cost capitalise lease lease property plant equipment group substantially risk reward ownership classified finance lease finance lease capitalise start lease fair value present value minimum lease payment low rental obligation net finance charge include debt asset acquire finance lease depreciate accordance group policy property plant equipment interest element finance cost charge income lease term lease substantially risk reward ownership transfer group classify operating lease payment operating lease charge income straightline basis period lease note roche group consolidate financial statement business combination goodwill business combination account purchase method accounting cost acquisition cash pay plus fair value date exchange purchase con sideration give exchange control net asset acquire company cost acquisition include directly attributable incidental cost acquire identifiable asset liability initially recognise fair value group acquire ership acquire company asset liability recognise fair value extent group interest minority interest record minoritys proportion pre acquisition carry amount acquire asset liability goodwill record surplus cost acquisition group interest fair value identifiable net asset acquire goodwill fair value adjustment record asset liability acquire company record local currency company goodwill amortise useful life straightline basis estimate useful life goodwill year goodwill arise investment associate company surplus cost investment initial value investment apply equity method goodwill record investment associate company amortisation include income associate company intangible asset patent licence trademark intangible asset initially record fair value asset acquire business combination fair value allocate acquisition accounting acquire business combination initial fair value cost intangible asset amortise useful life straightline basis estimate useful life low legal duration economic useful life maximum year impairment nonmonetary asset evidence asset impair recoverable asset calculate impairment assessment carry recoverable asset high net selling price value use carrying carry reduce recoverable value reduction report income statement impairment loss value use calculate estimate cash flow generally fiveyear period extrapolate projection subsequent year discount appropriate longterm pretax interest rate impairment loss arise useful life asset question review necessary future depreciationamortisation charge accelerate impairment financial asset discuss financial asset policy inventory inventory state low cost net realisable value cost finish good work process comprise raw material direct labour directly attributable cost overhead base normal capacity production facility borrowing cost include cost determine weighted average method net realisable value estimate selling price cost completion selling expense note roche group consolidate financial statementsaccount receivable account receivable carry original invoice allowance doubt fulaccount allowance record difference carry recoverable objective evidence group able collect allamount cash cash equivalent cash cash equivalent comprise cash hand time current balance bank similar institution readily convertible know amount cash subject insignificant risk change value maturity month date acquisition definition cash flow statement equity instrument group holding equity instrument record deduction equity original cost acquisition consideration receive subsequent resale equity instru ment movement report change equity instrument acquire primarily meet obligation arise respect certain group debt instrument december group revise classification obligation repurchase equity instrument base development international practice exposure draft pro pose change ifrs publish iasb reclassify liability measure present value final obligation discount appropriate longterm pretax interest rate discuss note position refinance obligation remain december debt instrument debt instrument initially report cost proceed receive net transaction cost subsequently report amortise cost effective interest method extent debt instrument hedge qualify fair value hedge carry value hedge item adjust fair value movement attributable risk hedge discount net proceed receive principal value redemption amortise duration debt instrument recognise interest expense income statement issue convertible debt instrument cost liability portion initially calculate market interest rate equivalent nonconvertible instrument remainder net proceed allocate equity conversion option report equity defer income tax liability equity conversion option share consolidated subsidiary portion net proceed attributable option record minority interest liability element subsequently report amortise cost amortisation debt discount release defer tax liability recognise income statement duration debt instrument value equity conversion option record equity change future period limited conversion prefer stock substance financial liability equity instrument classified longterm debt balance sheet relate dividend payment treat interest expense note roche group consolidate financial statement provision provision recognise legal constructive obligation incur probably lead outflow resource reasonably estimate provision record estimate ultimate liability expect arise take account foreign currency effect time value money material contingent liability disclose existence obligation confirm future event obligation measure reasonable reliability contingent asset recognise disclose inflow economic benefit probable fair value fair value financial asset liability instrument exchange knowledgeable willing party arm length transaction determine reference quote market price adjust estimate transaction cost incur actual transaction use establish estimation technique option pricing model estimate discount value cash flow fair value balance sheet date approximately line report carry value specifically mention note consolidated financial statement financial asset financial asset principally investment include marketable security classify heldfortrade availableforsale heldtomaturity originate group heldfor trade financial asset acquire principally generate profit shortterm fluctuation price heldtomaturity financial asset security fix maturity group intent ability hold maturity financial asset originate group loan longterm financial asset create group acquire issuer primary market financial asset consider availableforsale financial asset initially record cost include transaction cost purchase sale recognise settlement date heldfortrade financial asset subsequently carry fair value change fair value record financial income period inwhich arise heldtomaturity financial asset subsequently carry amortise cost effective interest rate method availableforsale financial asset subsequently carry fair value unrealise change fair value record equity avail ableforsale financial asset sell impair dispose cumulative gain loss previously recognise equity include financial income current period financial asset originate group subsequently carry amortise cost financial asset assess possible impairment balance sheet date impairment charge record objective evidence impairment issuer bankruptcy default significant financial difficulty financial asset carry amor tise cost impairment charge difference carry value recover able calculate estimate future cash flow discount appropriate longterm pretax interest rate availableforsale financial asset impairment charge currently carry equity difference original cost net previous impairment fair value note roche group consolidated financial statementsas december group revise accounting estimate impairment financial asset base development international practice exposure draft propose change ifrs publish iasb addition impairment trigger availablefor sale financial asset market value original cost net previous impairment sustain sixmonth period consider impaired decrease market price original cost net previous impairment orfor sustained sixmonth period consider objective evidence impairment movement fair value record equity isobjective evidence impairment asset sell dispose derivative derivative financial instrument initially record cost include transaction cost derivative subsequently carry fair value apart derivative designate qualify cash flow hedge instrument change fair value record asfinancial income period arise hedging purpose hedge accounting hedging relationship type fair value hedge hedge particular risk change fair value recognise asset liability cash flow hedge hedge particular risk change time offuture cash flow hedge net investment foreign entity hedge particular risk change carry value net asset foreign entity qualify hedge accounting hedging relationship meet strict condition documentation probability occurrence hedge effectiveness reliability measurement condition meet relationship qualify hedge accounting case hedge instrument hedge item report independently nohedge relationship particular derivative report fair value change fair value include financial income qualify fair value hedge hedge instrument record fair value hedge item record previous carrying value adjust change fair value attributable hedged risk change fair value report financial income qualify cash flow hedge hedge instrument record fair value portion ofany change fair value effective hedge include equity remain ineffective portion report financial income hedge relationship hedge firm commitment highly probable forecast transaction cumulative change offair value hedge instrument record equity include initial carrying value asset liability time recognise qualify cash flow hedge cumulative change fair value hedge instrument record equity include financial income time forecast transaction affect net income qualifying hedge net investment foreign entity hedge instrument record fair value portion change fair value effective hedge include equity remain ineffective portion record financial income hedge instrument derivative equity case entity dispose cumulative change fair value hedge instrument record equity include financial income time disposal note roche group consolidate financial statement change accounting policy line develop international practice cash discount classify deduction sale previously cash discount report marketing distribution expense comparative figure financial statement sale marketing distribution expense reduce million swiss franc impact operating profit net income reclassification comparative segment discontinuing operation information restate international financial reporting standard revise new standard interpretation effective january significant effect group financial statement late inter national accounting standard board publish revise version ia financial instrument disclosure presentation revise version ia financial instrument recognition measurement improvement international accounting standard whichmake change exist standard adopt possible early adoption group currently assess potential impact new standard exposure draft publish notably sharebase payment business combination final standard expect early financial risk management financial risk management group govern policy guideline approve senior management policy guideline cover foreign exchange risk interest rate risk market risk credit risk liquidity risk group policy guideline cover area cash management investment excess fund raise short longterm debt group company report detail financial instrument outstanding financial liquidity togroup treasury monthly basis group subsidiarie genentech chugai treasury operation operational independence whilst work afinancial risk management framework consistent rest group com pliance group financial risk management policy guideline oversee financial risk manager group accordance risk management guideline continue monitor risk deem appropriate certain risk significantly alter use financial instrument derivative group management believe order create optimum value group desirable eliminate mitigate possible market fluctuation group engage financial transaction trading speculative pur pose shortterm position enter advantage market opportunity asset management foreign exchange risk group operate world expose movement foreign currency affect ingit net income financial position express swiss franc group continue monitor currency exposure appropriate enter transaction aim preserve value asset commitment anticipate transaction group use forward contract foreign currency option optimise certain anticipate foreign exchange revenue cash flow financing transaction note roche group consolidated financial statementstransaction exposure arise local currency pay receive trans action denominate foreign currency vary change exchange rate group company income primarily local currency significant expendi ture especially purchase good resale interest repayment loan foreign currency similarly transaction exposure arise net balance monetary asset heldin foreign currency group company manage exposure local level necessary mean financial instrument option forward contract addition group treasury monitor total worldwide exposure help comprehensive datum receive monthly basis translation exposure arise consolidation foreign currency denominate finan cial statement group foreign subsidiary effect group consolidated equity show currency translation movement group hedge significant net investment foreign currency take foreign currency loan issue foreign currency denominate debt instrument major translation exposure monitor regular basis significant group cash outflow research development production admin istration denominate swiss franc small proportion group cash inflow swiss franc denominate result increase value swiss franc rela tive currency adverse impact consolidate net income similarly relative fall value swiss franc favourable effect result publish swiss franc interest rate risk interest rate risk arise movement interest rate adverse effect thegroup net income financial position change interest rate cause variation interest income expense interestbeare asset liability addition affect market value certain financial asset liability instrument describe follow section market risk interest rate group major debt instrument fix describe note reduce group exposure change interest rate group company manage shortterm interest rate risk local level necessary financial instrument interest rate forward contract swap option market risk financial asset change market value certain financial asset derivative instrument affect net income financial position group financial longterm asset hold strategic purpose marketable security hold fund management purpose risk loss value reduce review prior invest continuous monitoring performance investment change risk profile investment equity bond debenture fix income instrument enter basis approve guideline regard liquidity credit rating credit risk credit risk arise possibility counterparty transaction unable unwilling meet obligation cause financial loss group trade receivables subject policy active risk management focusse assessment country risk credit availability ongoing credit evaluation account monitor procedure signifi concentration trade receivables counterparty credit risk group large number customer wide geographical spread country risk limit exposure continuously monitor exposure financial asset credit risk control set ting policy limit credit exposure highquality counterpartie ongoing review credit rating limit individual aggregate credit exposure accordingly note roche group consolidate financial statement liquidity risk group company need sufficient availability cash meet obligation individual company responsible cash management include shortterm investment cash surplus raise loan cover cash deficit subject guidance group certain case approval group level group maintain sufficient reserve cash readily realisable marketable security meet liquidity requirement times addition strong international creditworthiness group allow efficient use international capital market financing purpose change group organisation millions chf list major group subsidiary associate company include note change group organisation follow onetime impact income statement vitamin fine chemical business impairment net asset disposal vitamin fine chemical business chugai transaction total disposal vitamin fine chemical business discuss note invest ment chugai discuss note disetronic effective group acquire control interest disetronic public company headquarter burgdorf switzerland disetronic world leader research development commercialisation insulin pump injection system treatment diabete disetronic infusion system division roche diagnostic diabetes care business area sale disetronic infusion system division year end march million swiss franc acquisition process disetronic injection system simultaneously resold disetronic founder chairman continue operate independent company group interest disetronic acquisition approve extraordinary general meeting disetronic shareholder april clear relevant antitrust authority group pay shareholders disetronic swiss franc cash roche nonvoting equity securities disetronic share net consideration pay million swiss franc million swiss franc cash million swiss franc form roche nonvoting equity security addition incidental cost million swiss franc allocation total purchase consideration million swiss franc follow net asset acquire goodwill intangible asset defer income taxis cash net asset liability total goodwill acquire intangible asset amortise straightline basis year year respectively note roche group consolidated financial statementsfollowing acquisition restructuring programme announce result restruc ture charge million swiss franc record operating expense restructure programme substantially complete mid igen group acquire control interest igen closing transaction expect february described note subsequent event isotechnika march july group acquire interest isotech nika inc isotechnika total million swiss franc isotechnika life sciences com pany headquarter canada develop immunosuppressive therapeutic drug use organ transplant patient treatment autoimmune disease follow acquisition group expect material transaction isotechnika access development milestone payment respect renal transplantation drug isatx materiality transaction group potential exercise significant influence isotechnika accordingly isotechnika report associate company million swiss franc goodwill arise acquisition balance acquisition price report investment associate company antisoma december group acquire interest antisoma plc antisoma million swiss francs antisoma british biopharmaceutical company develop prod uct treatment cancer follow acquisition group expect material transaction antisoma access development milestone payment respect oncology product portfolio materiality transaction group potential exercise significant influence antisoma accordingly antisoma report asan associate company million swiss franc goodwill arise acquisition balance acquisition price report investment associate company cash flow change group organisation show table amount net cash balance acquireddiveste companybusiness acquisition subsidiary associate company disetronic chugai acquisition total divestment subsidiary associate company vitamin fine chemical business divestment total note roche group consolidate financial statement segment information millions chf divisional information roche genentech chugai prescription prescription prescription otc segment revenue segment revenuedivisional sale interdivisional sale divisional sale party operate profit exceptional item amortisation goodwill major legal case change group organisation segment resultsoperate profit segment asset liabilitie divisional asset segment asset segment asset nonsegment asset total asset divisional liability segment liability segment liability nonsegment liability total liability segment information capital expenditure depreciation amortisation intangible asset impairment longterm asset restructuring expense research development cost income associate company investment associate company number employee chugai prescription business segment include result newly merge chugai company include nippon roche business october include result nippon roche period september results chugais otc business include otc business segment result chugai prescription business segment include million swiss franc million swiss franc writeoff fair value adjustment inventory arise acquisition accounting chugai note fair value adjustment write line inventory turnover fully writtenoff end quarter note roche group consolidated financial statementstotal core vitamin pharmaceutical diagnostic business fine chemical group note roche group consolidate financial statement geographical information sale party destination segment asset capital expenditure switzerland european union rest europe europe north america latin america japan rest asia asia africa australia oceania segment total nonsegment asset consolidate total sale party destination segment asset capital expenditure switzerland european union rest europe europe north america latin america japan rest asia asia africa australia oceania segment total nonsegment asset consolidate total note roche group consolidate financial statement genentech effective september group acquire majority interest approximately genentech inc biotechnology company united states june group exer cise option acquire remain share genentech june point genentech own subsidiary group july october march group complete public offering genentech common stock result group majority interest genentech issue additional share common stock connection equity compensation plan issue additional share purpose affiliation agreement group genentech provide thing genentech establish stock repurchase programme maintain group percentage ownership interest genentech december group interest genentech common stock genentech publicly trade list new york stock exchange symbol dna genentech prepare financial statement conformity accounting principle generally accept united states gaap file quarterly basis securities exchange commission sec certain consolidation entry difference requirement international financial reporting standard ifrs gaap difference genentech standalone result gaap basis result genentech consolidate roche group accordance ifrs arereconcile table usd chf usd chf million million million million operate margin gaap basis redemption cost special litigation item operate margin nonus gaap basis add deduct difference consolidation entry add redemption cost difference consolidation entry operating profit exceptional item ifrs basis add deduct exceptional item amortisation goodwill million usd annually major legal case segment resultoperate profit ifrs basis add deduct nonoperate item ifrs basis financial income income taxis net income ifrs basis minority interest percentage average year income applicable minority interest ifrs basis note roche group consolidate financial statement difference ifrs gaap follow acquisition group interest genentech june analysis carry acquisition accounting identify amount attributable inprocess research development iprd genentech gaap financial statement item record adjustment equity onetime expense ifrs item classify separate asset date acquisition form goodwill year subsequent goodwill amortisation expense respect iprd group result ifrs genentech adopt accounting standard fas fas effective january goodwill long amortise subject impairment test annually ifrs goodwill contin ue amortise subject testing impairment effective july genentech apply fasb interpretation fin consoli dation variable interest entity gaap financial statement result genentech consolidate certain leasing structure gaap financial statement dis close detail genentechs sec filing report group annual financial state ment genentech leasing structure consolidate group result accordance ifrs property plant equipment concern capitalise depreciated lease finance report longterm debt difference ifrs gaap relatively minor impact genentech stock repurchase stock option december genentechs board director authorise stock repurchase programme repurchase million dollar genentechs common stock december genentech repurchase common stock worth million dollar million swiss franc early genentech repurchase common stock worth million dollar million swiss franc early stock repurchase programme expire june genentech repurchase million dollar million swiss franc common stock genentech stock option plan adopt amend plan allow thegrante stock option stock award stock appreciation right employee director consultant genentech detail show table number option outstanding january grant exercised cancellation outstanding end year exercisable detail option grant expiry date average exercise pricein usd proceed option exercisedin million usd fair value option grant blackschole option valuation model million dollar millions swiss franc note roche group consolidated financial statement option exercise average exercise priceinusd proceed million dollar millions swiss franc term option outstanding december option outstanding option exercisable weighted average weighted weight year remain average average number contractual exercise number exercise range exercise price usd outstanding life price usd exercisable price usd total net accounting effect genentech stock repurchase stock option record minority interest note matter discuss note group record income million swiss franc expense million swiss franc respect certain litigation matter genentech january group issue lyon zero coupon dollar note exchange able genentech share note convert group percentage owner ship genentech decrease approximately note chugai december roche chugai announce enter alliance create lead researchdriven japanese pharmaceutical company formed merger chugai exclude genprobe roche japanese pharmaceuticals subsidiary nippon roche term alliance chugai nippon roche indepen dently value roche agree additional cash contribution order bring roche par ticipation agree combine value alliance approve shareholders chugai annual general meeting june newly merge company know chugai fully consolidated subsidiary group roche majority shareholder ownership december minority interest transaction process lateseptember roche acquire public tender offer approximately mil lion shares chugais outstanding share price jpy share total cash flow group result tender offer billion japanese yen million swiss franc immediately tender offer roche subscribe issue chugai million new share price jpy share result cash contribution tochugai billion japanese yen million swiss franc september closing tender offer roche chugai complete spinoff shareholding ingen probe californiabase diagnostic subsidiary register shareholder july note roche group consolidate financial statement october chugai merge nippon roche prior merger nippon roche issue convertible bond roche group roche obligation succeed chugai october roche acquire additional share chugai conversion bond pro portion share issue chugai conversion convertible bond previously issue chugai party chugai roches ownership reach result cash contribution billion japanese yen million swiss franc ongoing basis roche convert remain roche chugai share correspond conversion remain chugai roche maintain ownership chugai purchase consideration closing transaction october transaction account purchase method accounting consideration pay roche chugai consist firstly public tender offer secondly subscription new chugai share con version roche relate minority shareholder thirdly net asset nippon roche attributable minority shareholder nippon roche public company net asset nippon roche value reference fair value chugai share acquire exchange allocation show table jpy billion chf million public tender offer subscription billion jpy convertible bond billion jpy imply value nippon roche transaction cost purchase consideration chugai acquisition accounting market value chugai share acquire billion japanese yen million swiss franc correspond market capitalisation chugai prior transaction purchase consideration billion japanese yen million swiss franc represent surplus billion japanese yen million swiss franc market value chugai share acquire surplus writtenoff record net asset chugai exceed market capitalisation result transaction gain billion japanese yen million swiss franc arise disposal nippon roche accordingly net income billion japanese yen million swiss franc recognise income statement amount acquire net asset chugai show table allocate good include billion japanese yen million swiss franc attributable inprocess research development international financial reporting standard item classify separate asset date acquisition form goodwill net asset acquire jpy billions chf millionsa property plant equipment goodwill intangible asset inventory defer income taxis liabilitie postemployment benefit provision net asset liability minority interest total translate september exchange rate jpy chf note roche group consolidate financial statementsongoe impact purchase accounting october chugais result include group consolidated financial state ment chugai prescription show separate business segment segment informa tion chugai prescription business segment include result newly merge chugai company include nippon roche business october include result nippon roche period september results chugais otc business include otc business segment segment information give note fair value adjustment arise acquisition accounting follow impact group financial statement quarter onwards jpy chf jpy chf jpy chf billion million billion million billion millionsa writeoff fair value adjustment inventory depreciation property plant equipment amortisation acquire intangible asset amortisation goodwill impact operating profit defer income taxis impact net income translate december exchange rate jpy chf fair value adjustment inventory fully writtenoff line inventory turnover end quarter goodwill acquire intangible asset amortise straightline basis year year respectively local statutory financial year june chugais annual general meeting approve change local statutory finan cial yearend march december accordingly chugai ninemonth local fiscal term begin april twelvemonth fiscal term begin january report roche group chugai continue report international finan cial reporting standard draw date rest roche group dividend dividend distribute thirdpartie hold chugai share total mil lion japanese yen million swiss franc october december million japanese yen million swiss franc record minority interest note dividend pay chugai roche eliminate consolidation intercompany item restructuring plan january chugai announce detail restructure plan involve closure sale certain plant facility japan april chugai announce theadditional closure plan research operation subsidiary group result restructure cost billion japanese yen million swiss franc record restructure programme substantially complete december share repurchase chugai repurchase common share total consideration billion japanese yen million swiss franc result group ownership chugai increase goodwill increase million swiss franc chugai annual general shareholder meeting june authorise repurchase common share maximum billion japanese yen note roche group consolidate financial statement stock acquisition right chugai adopt stock acquisition right programme programme allow grant right employee director chugai right entitle holder purchase chugai share specify exercise price detail show table number right outstanding january grant exercised cancellation outstanding end year exercisable detail right grant expiry date june average exercise pricein jpy proceed right exercisedin million jpy fair value right grant blackschole option valuation model million japanese yen millions swiss franc term right outstanding december right outstanding right exercisable weighted average year remain number contractual exercise number exercise year grant outstanding life price jpy exercisable price jpy net accounting effect exercise chugai stock acquisition right record minority interest note vitamin fine chemical division millions chf effective september receive final regulatory approval group complete sale global vitamin fine chemical business vfc business dutch company dsm consideration sale million euro million swiss franc con siste million euro million swiss franc cash million share dsm market value million euro million swiss franc term final purchase agreement dsm share acquire group block year note roche group consolidated financial statementsthe sale cashanddebtfree basis cash receive dsm reduce million euro million swiss franc reflect net debt vfc business furthermore term final purchase agreement dsm certain agree purchase price adjustment mechanism mainly relate work capital level vfc business mechanism result purchase price reduction million euro million swiss franc final amount arise mechanism include net debt calculation subject review approval group dsm liable change impairment charge million swiss franc record december impairment charge million swiss franc record june base assessment respective date difference expect net pro ceed disposal net asset vfc business take account residual obligation retain roche group preliminary assessment december show additional loss disposal million swiss franc arise onthe disposal vfc business final assessment follow review approval group dsm transaction summarise table eur millions chf million consideration net debt adjustment purchase price adjustment mechanism net proceed dsm cash dsm share incidental transaction cost net asset vfc business net impairment charge accrual residual obligation retain roche group gainloss disposal preliminary assessment disposal result tax benefit currently estimate mil lion swiss franc cash inflow disposal net cash balance million swiss franc hold company vfc business million swiss franc follow sale vfc business certain asset liability vitamin fine chemical division mainly associate vitamin case remain group describe section vitamin case addition group give dsm certain indemnity respect remedial action site vfc business require environmental law arrangement place utilisation certain asset certain purchasing contract adopt dsm preferred supplier pharmaceutical ingredient arrangement group guarantee purchase period year begin january product sale value total million euro group reimburse dsm unutilised amount arrangement consist certain residual obligation fully accrue note roche group consolidate financial statement vitamin fine chemical division show discontinuing operation con solidate result amount include group consolidated income statement thevitamin fine chemical division show table result thevfc business include consolidated result group sale september vitamin case vitamin vfc business residual amount fine chemical division income statement sale party expense operate profit exceptional item amortisation goodwill major legal case change group organisation operate profit result associate company financial income profit taxis income taxis profit taxis minority interest net income amount group consolidate balance sheet vfc business show table december december balance sheet property plant equipment longterm asset current asset total asset longterm debt noncurrent liability current liability total liability net asset amount include group consolidate cash flow statement vfc business show table cash flow result vfc business include consolidated result group sale september statement cash flow operating activity financing activity invest activity net effect currency translation cash increase decrease cash note roche group consolidated financial statementsvitamin case follow settlement agreement department justice pricing practice vitamin market overall settlement agreement class action suitbrought buyer bulk vitamin group record provision respect vitamin case provision group well estimate time total liability arise take account currency movement time value money provision legal fee record separately december december base development litigation recent settlement negotiation group record additional provision million swiss franc respectively january district columbia circuit court appeal rule nonus plaintiff bring claim court antitrust law allege damage suffer trans action outside united states connection vitamin case defendant include roche file petition ask supreme court review case december supreme court decide consider appeal defendant provision record respect litigation eventual outcome uncertain stage total payment year million swiss franc million swiss franc charge provision previously record payment include million dollar million swiss franc direct customer united states group seek resolve remain outstanding issue time final amount involve uncertain remain provision record total million swiss franc base current litigation recent settlement agreement provision areall consider shortterm cash outflow expect arise discount time value money consider material case litigation negotiation progress possible ultimate liability different provision currently record disposal process liability respect vitamin case remain roche group roche dsm sign indemnity cooperation agreement roche provide dsm certain indemnity guarantee connection vitamin case major legal case million chf igen litigation writeoff intangible asset release provision genentech legal case payment settlement additional provision total note roche group consolidate financial statement igen litigation february united states district court maryland enter judgement civil litigation roche diagnostic gmbh germany rdg igen international inc igen claim relate licensing igen electrochemiluminescence ecl technology rdg court conclude breach licence agreement material igen right terminate licence agreement award igen million dollar compensatory damage million dollar punitive damage july united states court appeals fourth circuit reverse substantial damage award rdg court reverse find rdg engage unfair competition continuation patent lawsuit igen rdgs affiliate company set aside claim court eliminate basis award million dollar punitive damage rdg court hold rdg violate imply covenant good faith fair deal license agreement set aside award million dollar compensatory damage claim total court eliminate million usdollar million dollar judgement enter rdg court leave intact thejurys award remain damage find igen terminate license agreement rdg igen notify rdg igen terminate license agreement july group igen announce plan thegroup acquire igen thisacquisition expect complete february note previous license agreement terminate group writtenoff intangible asset technology record time acquisition corange group roche group net book value million swiss franc time group release income million swiss franc litigation provision balance provision remain outstanding compensatory damage award net amount expense totalling million swiss franc record expense major legal case march rdg pay million dollar collateral deposit account relation theigen litigation follow entry final judgement rdg pay remain million usdollar million swiss franc respect remain compensatory damage igen collateral deposit account repay group net cash inflow transaction million swiss franc genentech legal case group record income million swiss franc respect certain litigation settlement include litigation involve amgen group record provision million swiss franc respect certain litigation matter include litigation involve thecity hope june genentech announce los angeles county superior court jury vote toaward city hope medical center approximately million dollar compensatory damage base find breach agreement genentech city ofhope june jury vote award city hope million dollar punitive damage case september genentech file notice appeal jury verdict damage awards california court appeal appeal process ongoing year depend scope review provision note roche group consolidate financial statementsbeen record award appeal process interest accrue total damage simple annual rate follow judgement interest million usdollar million swiss franc million dollar million swiss franc record asthe time cost provision interest expense note october genentech enter arrangement party insurance company post surety bond million dollar connection judgement arrange ment genentech pledge million dollar cash investment secure bond amount equivalent million swiss franc report restrict cash financial longterm asset note addition genentech party patent infringement suit file chiron corporation june district court eastern district california sacramento respect herceptin june court issue decision summary judgement motion file jury trial suit begin august follow phase trial base finding jury court enter judgement favour genentech november chiron file notice appeal court appeal federal circuit december genentech file notice crossappeal court appeal process ongoing august united states patent trademark office declare interference chiron patent involve lawsuit patent application exclusively license genentech university pennsylvania relate antiher antibody declare interference patent office determine substantial question inventor chiron patent invent technology involve entitle patent connection second patent infringement lawsuit file march genentech chiron discovery case currently stay january arbitration proceeding begin genentech tanox biosystems inc tanox july settlement crosslicensing agreement relate development manufacture certain antibody product direct immunoglobin include xolair tanox claim breach agreement genentech counterclaim genentech continue work arbitration process tanox party agree postpone decision arbitration early decision late february provision record respect arbitra tion outcome determine date financial statement august genentech amgen inc announce settlement patent litigation district court northern district california settlement agreement party agree dismiss claim counterclaim settlement amgen onetime payment genentech november genentech bayer settle breach contract action genentech bring bayer relate bayer manufacture sale factor viii license agreement bayer genentech settlement bayer onetime payment genentech income major legal case million swiss franc record respect settlement genentech party litigation describe genentech annual report quarterly sec filing matter far advanced matter refer note roche group consolidated financial statement employee benefit million chf wage salary social security cost postemployment benefit define benefit plan postemployment benefit define contribution plan employee benefit total employee remuneration charge employee benefit include relevant expenditure line function thenumber employee yearend employee benefit consist mainly life insurance scheme certain insurance scheme provide medical dental cover pension postemployment benefit millions chf employee cover retirement benefit plan sponsor group company nature plan vary accord legal regulation fiscal requirement economic con dition country employee employ majority plan define benefit plan large locate switzerland united states germany united kingdom japan postemployment benefit consist postretire ment healthcare life insurance scheme principally united states plan usually fund payment group employee trust independent group finance plan unfunded notably major define benefit plan germany liability obligation record group balance sheet amount recognise arrive operate profit postemployment define benefit plan follow current service cost interest cost expect return plan asset net actuarial gain loss recognise past service cost gain loss curtailment total include employee remuneration actual return plan asset million swiss franc negative return million swiss franc september group pay additional contribution million dollar mil lion swiss francs postemployment define benefit plan subsidiary fall market value plan asset payment include contri bution pay table account recognise surplus fund pension plan note group consolidated financial statement include actuarial calculation group pension expense andbalance note roche group consolidated financial statementsthe movement net asset liability recognise balance sheet postemployment define benefit plan follow begin year disetronic chugai vitamin fine chemical business total expense include employee remuneration contribution pay benefit pay unfunded plan currency translation effect end year amount recognise balance sheet postemployment define benefit plan follow fund plan actuarial present value fund obligation past present employee plan asset hold trust fair value plan asset excess deficit actuarial present value fund obligation unrecognise actuarial gain loss unrecognise past service cost net recognise asset liability fund obligation past present employee unfunded plan recognise liability actuarial present value unfunded obligation past present employee total recognise asset liability fund unfunded obligation past present employee report surplus recognise longterm asset deficit recognise liability postemployment benefit total net asset liability recognise amount include nonpension postemployment benefit scheme principally medical plan follow actuarial present value obligation past present employee plan asset hold trust fair value plan asset excess deficit actuarial present value fund obligation unrecognised actuarial gain loss net recognise asset liability amount recognise balance sheet postemployment define benefit plan pre dominantly noncurrent report longterm asset noncurrent liability plan asset fund plan include group equity instrument nonvoting equity security fair value million swiss franc note roche group consolidated financial statement group operate define benefit scheme country actuarial assumption vary base local economic social condition range assumption actuarial valuation significant define benefit plan country stable currency interest rate follows weight weight average range average range discount rate project rate remuneration growth expect rate return plan asset healthcare cost trend rate employee stock option equity compensation benefit millions chf roche option plan group offer nonvoting equity security option certain director management exercise price market price nonvoting equity security date issue option nontradable sevenyear duration vest phase basis year group cover obligation purchase nonvoting equity security derivative thereon note cost instrument report equity instru ment equity balance sheet option exercise cash receive credit equity instrument impact income statement employer social insurance cost administrative cost plan previous option compensation plan group purchase option directly party financial insti tution grant certain employee close exist option grant old plan continue option grant detail roche option plan show table number option outstanding january grant exercised cancellation outstanding end year exercisable detail option grant expiry date february february july andaugust average exercise price chf proceed option exercisedin millions chf fair value option grant blackschole option valuation modelin millions chf option exercise average exercise price chf proceed million chf note roche group consolidated financial statementsterm option outstanding december option outstanding option exercisable weighted average weighted weight year remain average average number contractual exercise number exercise year grant outstanding life price chf exercisable price chf total roche performance share plan group offer future nonvoting equity security award board discretion cash equivalent certain director key senior management programme establish beginning effect year nonvoting equity security grant depend individual salary level achievement performance target link group total shareholder return share nonvoting equity security combine relative group peer threeyear period date grant grant vest year final number nonvoting equity security award equivalent original grant depend final total share holder return performance approve board director close financial year settle number original grant outstanding december cost plan accrue vest period grant base final cash outflow estimate balance sheet date year cost ofthe plan million swiss franc million swiss franc report relevant operating expense category roche connect programme enable employee worldwide united states cer tain country regular deduction salary purchase nonvoting equity security administer independent party group make contribution programme allow employee purchase nonvoting equity security discount usually administrator purchase necessary nonvoting equity security directly market nonvoting equity security hold december programme operational october year cost plan million swiss franc million swiss franc report relevant operating expense category stock appreciation right employee certain subsidiary group receive stock appreciation right sar compensation sar exercise vest period year cash payment base market price ofthe group american depositary receipt adr point exercise exceed strike price grant price issuance number right outstanding january grant exercised cancellation outstanding end year exercisable note roche group consolidate financial statement detail right grant expiry date february december average exercise price usd fair value right grant blackschole option valuation model million dollar millions swiss franc right exercise average exercise price usd cash outflow million dollar millions swiss franc amount record consolidated financial statement expense million chf accrual million chf term right outstanding december right outstanding right exercisable weighted weight average average number exercise number exercise year grant outstanding expiry price usd exercisable price usd prior awards award award award total genentech chugai plan genentech stock option plan discuss note chugai stock acquisition right programme discuss note operating income millions chf royalty income gain disposal product total operating income ongoing alignment product portfolio group periodically dispose product line long consider core product september group announce sale protein design labs pdl business relate zenapax product worldwide disease indication organ transplantation group continue market zenapax transplantation indication point pdl option purchase cash receive million swiss franc october group complete sale amgen business relate neupogen product european union switzerland norway thecash receive million swiss franc disposal product concern book value gain disposal cash proceed disposal report operate profit roche prescription segment note roche group consolidate financial statement operating expense millions chf royalty expense restructuring expense impairment longterm asset total operating expense operating expense include million swiss franc restructuring expense million swiss franc impairment longterm asset pharmaceutical division restructuring programme report operate profit roche prescrip tion segment previously separately disclose income statement financial income millions chf gain sale equity security loss sale equity security gain labcorp transaction dividend income gain loss equity derivative net writedown impairment equity security net income equity security interest income gain sale debt security loss sale debt security writedown impairment longterm loan net interest income income debt security interest expense amortisation discount debt instrument gain loss interest rate derivative net time cost provision net interest expense foreign exchange gain loss net gain loss foreign currency derivative net net foreign exchange gain loss net financial income expense total net financial income gain labcorp transaction march july group sell remain share labcorp transaction result pretax gain incidental cost million swiss franc amount record financial income net pretax cash inflow million swiss franc addition group realise gain million swiss franc equity derivative enter connection disposal labcorp share group remain ownership interest labcorp outstanding derivative position labcorp equities note roche group consolidated financial statement impairment financial asset december group revise accounting estimate impairment financial asset addition exist impairment trigger describe note available forsale financial asset market value original cost net previous impairment sustain month period consider impaired fall market price original cost net previous impairment sustained sixmonth period consider objective evidence ofimpairment movement fair value record equity objective evidence impairment asset sell dispose result revision accounting estimate group record exceptional impairment charge million swiss franc effective december writedown impairment equity security million swiss franc arise availableforsale financial asset market value original cost sustain sixmonth period consider impair mainly relate equity security december market value limit sustained sixmonth period income taxis million chf income tax expense amount charge income statement follow current income taxis defer income taxis total charge income taxis group operate world subject income taxis different tax jurisdiction group calculate average expect tax rate weight average tax rate tax jurisdiction group operate rate increase operating income considerably high proportion pretax income case previous year cause increase group effective tax rate operating income typically occur jurisdiction high tax rate compare financial income group average expect tax rate stabilise group average expect tax rate increase significance genentech chugai cause increase rate offset ongoing improvement group structure group effective tax rate reconcile group average expect tax rate follow group average expect tax rate tax effect unrecognised tax loss gain sale labcorp share nontaxable incomenondeductible expense impairment financial asset difference continue business exceptional item effective tax rate note roche group consolidated financial statement impact impact impact impact profit tax income taxis tax rate profit tax income taxis tax rate continue business exceptional item effective tax rate amortisation goodwill major legal case change group organisation exceptional impairment financial asset continue business effective tax rate discontinuing business group effective tax rate income tax asset liability amount recognise balance sheet income taxis follow current income taxis current income tax asset current income tax liability net current income tax asset liability balance sheet defer income taxis defer income tax asset defer income tax liability net defer income tax asset liability balance sheet decrease current income tax asset reimbursement swiss withholding taxis tax receivable united states defer income tax asset recognise tax loss carry forwards extent realisation relate tax benefit probable group unrecognised tax loss include valuation allowance million swiss franc million swiss franc million swiss franc expire year remain million swiss franc loss expire year expiry limit defer income tax liability establish withholding tax taxis payable unremitted earning certain foreign subsidiary amount currently regard permanently reinveste unremitted earning total billion swiss franc december billion swiss franc defer income tax asset liability defer income tax charge credit attributable follow item property plant equipment restructure temporary intangible asset provision difference total net defer income tax asset liability begin year charge credit income statement charge credit equity disetronic disposal vitamin fine chemical business currency translation effect net defer income tax asset liability end year note roche group consolidate financial statement property plant equipment restructure temporary intangible asset provision difference total net defer income tax asset liability begin year charge credit income statement charge credit equity chugai currency translation effect net defer income tax asset liability end year property plant equipment million chf building land machinery improve construction land ment equipment progress total total net book value beginning year disetronic chugai disposal vitamin fine chemical business addition disposal transfer depreciation charge impairment charge currency translation effect end year december cost accumulate depreciation net book value finance lease december capitalise cost machinery equipment finance lease amount million swiss franc million swiss franc net book value asset amount million swiss franc million swiss franc operating lease future minimum annual payment noncancellable operating lease follow year year total minimum annual payment total operating lease rental expense million swiss franc million swiss franc group capital commitment purchase construction property plant equipment total billion swiss franc billion swiss franc note roche group consolidated financial statement goodwill millions chf net book value beginning year disetronic chugai amortisation charge impairment charge vitamin fine chemical impairment net asset currency translation effect end year december cost accumulate amortisation net book value genentech acquisition corange acquisition chugai acquisition disetronic acquisition total goodwill arise investment associate company classify theinvestment associate company note goodwill million swiss franc arise investment antisoma december reclassify goodwill previously publish balance sheet intangible asset millions chf patent licence acquisition trademark relate total total net book value beginning year disetronic chugai addition disposal amortisation charge impairment charge vitamin fine chemical impairment net asset igen litigation currency translation effect end year note roche group consolidate financial statement patent licence acquisition trademark relate total total december cost accumulate amortisation net book value genentech acquisition corange acquisition chugai acquisition disetronic acquisition kytril total kytril intangible asset arise purchase group global rights kytril granisetron smithkline beecham december million swiss franc group currently internally generate intangible asset development criterion forthe recognition asset meet associate company millions chf group investment associate company list account equity method share net income balance sheet value basilea pharmaceutica switzerland investment associate company total investment associate company goodwill arise investment associate company classify investment associate company goodwill million swiss franc arise investment antisoma december reclassify goodwill previ ously publish balance sheet note basilea pharmaceutica group own noncontrolle interest inbasilea pharmaceutica ltd basilea basilea swiss biotechnology company anti bacterial antifungal dermatology field group major investment associate tripath inc isotechnika antisoma additional information company give note transaction group associate company give note note roche group consolidate financial statement joint venture millions chf group interest joint venture report financial statement propor tionate consolidation method significant joint venture detailed bayer joint venture group stake bayer roche llc joint venture bayer group overthecounter otc field market distribute product aleve certain otc product united states effect group joint venture income statement balance sheet follow income statement sale expense net income taxis balance sheet longterm asset current asset noncurrent liabilitie current liability net asset financial longterm asset millions chf availableforsale investment heldtomaturity investment loan receivable longterm trade receivable restrict cash total financial longterm asset financial longterm asset hold strategic purpose classify non current effective interest rate heldtomaturity investment loan receivable comprise loan party term year restrict cash consist million dollar million swiss franc cash invest ment pledge genentech connection city hope litigation note cashset aside collateral certain lease agreement restrict cash include million dollar pay collateral deposit account respect igen litigation seenote million swiss franc pledge roche group company collateral connection obligation repurchase equity instrument note note roche group consolidate financial statement longterm asset millions chf recognise surplus fund pension plan prepay employee benefit total longterm asset longterm asset consist asset show separately group expect derive economic benefit year inventory million chf raw material supply work process finish good provision slowmove obsolete inventory total inventory inventory hold net realisable value carry value million swiss franc million swiss franc result disposal vitamin fine chemical business inventory decrease million swiss franc effective september note account receivable million chf trade account receivable note receivable provision doubtful account total account receivable december account receivable include amount denominate dollar equivalent billion swiss franc billion swiss franc amount denominate euro equivalent billion swiss franc billion swiss franc bad debt expense million swiss franc million swiss franc current asset millions chf accrue interest income prepaid expense derivative financial instrument receivables total current asset marketable security millions chf heldfortrade investment bond debenture availableforsale current investment share bond debenture money market instrument time account month total marketable security note roche group consolidated financial statementsmarketable security hold fund management purpose classify current investment hold strategic purpose classify noncurrent note share consist primarily readily saleable equity security bond debenture average effective contract maturity interest rate year year year total bond debenture year year year total bond debenture money market instrument generally fix interest rate range depend currency denominate theyare contract mature year december account payable million chf trade account payable taxis payable account payable total account payable accrue current liability millions chf defer income accrue payroll relate item interest payable derivative financial instrument accrue liability total accrue current liability note roche group consolidate financial statement provision contingent liability millions chf environmental legal restructuring provision provision provision total total beginning year chugai change group organisation vitamin case additional provision create utilise year major legal case additional provision create unused amount reverse utilise year provision additional provision create unused amount reverse utilise year increase discount passage time change discount rate currency translation effect end year current portion provision noncurrent portion provision total provision expect outflow resource year year year year total provision environmental legal provision provision include million swiss franc million swiss franc environman tal matter million swiss franc million swiss franc litigation includ e major legal case vitamin case provision environmental matter cover separate environmental issue number ofcountrie approximately half preexist company acquire group group record additional environmental provision respect certain indemnity give dsm respect remedial action site vfc business note bytheir nature amount time outflow difficult predict group estimate approximately half provide result cash outflow thenext year significant provision discount note roche group consolidated financial statementslegal provision consist mainly major legal case notably city hope medical center litigation note vitamin case note amount timing uncertainty outflow discuss note discount rate remain legal provision account balance consist number separate legal matter group company majority cash outflow expect occur year dependent development thevarious litigation significant provision discount major legal case describe note vitamin case describe note litigation matter currently significant describe carvedilol arbitration roche diagnostic gmbh rdg smithkline beecham cork ltd party arbitration concern rdgs termination carvedilol license agreement amend relate licensing comarkete carvedilol rdg submit claim damage arbitration tribunal zurich sub mitte counterclaim assert invalidity rdgs termination claim damage final decision arbitration tribunal expect early pro vision record rdg disclose seriously prejudice rdgs position inthis matter applera litigation october applera corporation applera file suit group superior court california file notice arbitration american arbi tration association superior court lawsuit arbitration demand claim con cerne interpretation enforcement contract group applera commercialisation polymerase chain reaction pcr technology claim seek termina tion certain contract declaration right obligation contract monetary damage relief unspecified allege breach agreement party december group file response arbi tration proceeding group generally deny claim counterclaim applera declaration concern respective right obligation party contract include allege breach applera obligation source certain enzyme group damage december group respond appleras complaint superior court proceeding petitioning court compel arbitration claim allege applera stay lawsuit pende completion arbitration court rule group petition hear trial date set arbitration proceed superior court lawsuit provision record respect matter outcome determined date financial statement promega litigation group file suit promega corporation promega allege patent infringement breach licence agreement relate polymerase chain reaction pcr technology litigation currently district court northern district california decision enforceability patent concern expect november group notify promega file non public qui tam action group district court eastern district west virginia march complaint file false claim act allege federal government overcharge purchase pcr enzyme product july federal government notify court decision intervene promegas complaint november court order complaint unseal group intend file motion dismiss complaint provision record respect litigation note roche group consolidate financial statement restructure provision arise plan programme materially change scope business undertaken group manner business conduct provision include cost necessarily entail restructuring associate ongoing activi tie group expect outflow include remain million swiss franc relat ing restructure disetronic million swiss franc relate closure cost pharmaceutical division restructuring announce remain amount respect obligation employee arise pharma ceutical division restructure previous restructuring plan timing cash outflow reasonably certain global basis show table significant provision discount provision provision consist claim arise trade provision group company fit category timing cash outflow bytheir nature uncertain good estimate show table provision discount time value money consider material case contingent liability operation earning group continue time time vary degree tobe affect political legislative fiscal regulatory development include relate environmental protection country operate industry group engage subject physical risk kind nature frequency ofthese development event cover insurance effect future operation earning predictable note respect vitamin case note respect major legal case group enter strategic alliance company order gain access topotential new product utilise company help develop group potential new product potential future payment certain collaboration partner achieve certain milestone define collaboration agreement group good esti mate future commitment payment million swiss franc million swiss franc million swiss franc noncurrent liability millions chf defer income longterm liability total noncurrent liability note roche group consolidate financial statement debt million chf debt instrument amount bank financial institution capitalise lease obligation obligation repurchase equity instrument borrowing total debt report longterm debt shortterm debt total debt repayment term debt year year year year year total debt lyon zero coupon dollar exchangeable note reflect year holder note request group purchase note fair value debt instrument billion swiss franc billion swiss franc fair value total debt billion swiss franc billion swiss franc iscalculate base present value future cash flow instrument discount market rate interest instrument similar credit status cash flow maturity period pledge group asset connection debt note theobligation arise lease genentech support restrict cash million usdollar million swiss franc addition obligation secure property plant equipment net book value million swiss franc december amount bank financial institution interest rate amounts primarily denominate dollar euro average approximately repayment date vary year million swiss franc million swiss franc year note roche group consolidate financial statement debt instrument carry value group debt instrument give table effective interest rate european medium term note programme bond october principal million euro bond august principal million pound sterling bond october principal million dollar swiss franc bond bullet march principal billion swiss franc rodeo march principal billion swiss franc dollar bond chameleon july principal billion dollar swiss franc convertible bond helveticus dividendlinke convertible bond july principal billion swiss franc zero coupon dollar exchangeable note lyon april principal billion dollar lyon iii principal billion dollar lyon january principal billion dollar lyon july principal billion dollar japanese yen exchangeable bond sumo march principal billion japanese yen limited conversion prefer stock november japanese yen convertible bond issue chugai series chugai pharmaceutical unsecured convertible bond september principal billion japanese yen total debt instrument issue new debt instrument net proceed show table european medium term note programme eurodenominate bond issue april sterlingdenominated bond issue august dollardenominated bond issue october total issue year note roche group consolidated financial statementsrepayment redemption conversion debt instrument net cash outflow show table bullet swiss franc bond repayment principal date march lyons dollar exchangeable note exercise group option redeem principal plus accrued original issue discount oid april helveticus swiss franc convertible bond additional cash payment chf bond conversion remain principal date july samurai japanese yen bond repayment principal date total repayment retirement year conversion helveticus swiss franc convertible bond date july remain swiss franc convertible bond originally issue convert nonvoting equity security genussscheinea total nonvoting equity security meet conversion obligation helveticus bond accordance term bond additional cash payment chf bond conversion remain principal conversion reduce debt million swiss franc million swiss franc form nonvoting equity security million swiss franc form cash term outstanding convertible debt instrument lyon iii note exchangeable american depositary share adss exchange ratio exchange adss usd principal maturity note group purchase note cash option holder purchase price usd principal note usd usd respectively addition note redeemable option group time issue price plus accrue original issue discount oid ifthe note outstanding december exchange require nonvoting equity security meet obligation lyon note exchangeable genentech share exchange ratio genentech share usd principal time maturity note group right pay cash equal market value genentech share lieu deliver genentech share group purchase note cash option holder january january purchase price usd principal note usd usd respectively addition note redeemable option group time january issue price plus accrue original issue discount oid note outstanding december exchange require genentech share meet obligation note convert group percentage ownership genentech decrease approximately lyon note exchangeable adss exchange ratio exchange adss usd principal maturity note group purchase note cash option holder january july july purchase price usd principal note usd usd usd respectively addition note redeemable option group time july issue price plus accrue original issue discount oid note outstanding december exchange require nonvoting equity security meet obligation note roche group consolidate financial statement sumo bond jpy par value exchangeable nonvoting equity security roche holding ltd bond redeemable maturity issue price plus accrue original issue discount oid bond outstanding december exchange require nonvoting equity security tomeet obligation limited conversion prefer stock limit conversion prefer stock substance afinancial liability equity instrument classified longterm debt balance sheet relate dividend payment treat interest expense thepar value share usd share subject mandatory redemption november par plus accrued annual interest share exchangeable option holder nonvoting equity security redeemable option holder par plus accrued annual interest november year share outstand ing december convert require nonvoting equity security meet obligation series chugai pharmaceutical unsecured convertible bond bond jpy par value convertible share chugai conversion option bondholder time date september bond redeemable maturity issue price bond outstanding december convert require chugai share exactly meet obligation group percentage ownership chugai affect conversion group bond convertible chugai share mirror chugai outstanding party note unamortised discount include carry value debt instrument follow unamortised discount swiss franc bond dollar bond euro bond sterle bond zero coupon dollar exchangeable note japanese yen exchangeable bond total unamortised discount derivative financial instrument millions chf appropriate circumstance group use derivative financial instrument risk management trading strategy discuss note derivative financial instrument carry fair value method determine fair value describe note foreign currency derivative forward exchange contract swap option interest rate derivative swap derivative total carrying value derivative financial instrument note roche group consolidate financial statement asset liability recognise current asset accrue current liability total net asset liability recognise hedge accounting group accounting policy hedge accounting describe note require qualify hedge accounting hedging relationship meet strict condition ondocumentation probability occurrence hedge effectiveness reliability measurement describe note group financial risk management policy cover foreign exchange risk interest rate risk market risk credit risk liquidity risk deem appropri eat certain risk alter use derivative transaction consider hedge economic term require condition meet relationship qualify hedge accounting case hedge instru ment hedged item report independently hedge relationship mean derivative report fair value change fair value include financial income group generally limit use hedge account certain significant transaction conse quently december group fair value hedge cash flow hedge hedge net investment foreign entity meet strict requirement qualify hedge accounting apart describe igen acquisition group sub sidiary genentech connection propose acquisition igen group contribute million dollar igen purchase igen share million dollar give total cash outflow million dollar group contribute million dollars equity acquisition vehicle remain million dollar fund liquid fund hold swiss franc euros group enter forward contract buy million dollar swiss franc million dollar euro order hedge foreign exchange risk arise movement dollar exchange rate ward rate chfusd eurusd value datei february fair value forward contract december nega tive million swiss franc negative million swiss franc respectively genentech nonus dollar cash flow future royalty income development expense expect year hedge transaction exposure genentech enter derivative financial instrument option forward contract instrument outstanding december genentech equity investment biotechnology company subject great risk market fluctuation stock market general manage exposure genentech enter derivative finan cial instrument zero cost collar forward contract december instrument designate qualify cash flow hedge record balance sheet fair value million swiss franc matter describe genen tech annual report quarterly sec filing movement fair value reserve designate cash flow hedge include note note roche group consolidate financial statement equity share capital december share capital roche holding ltd group parent company consist share precede year share bearer share group maintain register shareholder base information supply tothegroup shareholder group pool voting right own ofthe issue share describe note base information supply thegroup novartis international ltd basel affiliate own participation issue share nonvoting equity security genussscheine december nonvoting equity security issue prece ing year swiss company law nonvoting equity security nominal value share capital issue contribution show asset balance sheet roche holding ltd nonvoting equity security confer right share participate net profit remain proceed liquidation follow repayment nominal value share participation certificate accordance law article incorporation roche holding ltd company entitle times exchange nonvoting equity security share participation certificate dividend april shareholder approve distribution dividend swiss franc share nonvoting equity security swiss franc respect business year distribution holder outstanding share nonvoting equity security total million swiss franc million swiss franc record retain earning board propose dividend business year swiss franc share nonvoting equity security subject approval annual general meeting april equity instrument follow redemption lyon exchangeable note april note light ongoing restructure group treasury operation debt financing group carry comprehensive review arrangement cover potential conversion obligation arise convertible debt instrument group refinance instrument cover potential obligation deliver nonvoting equity security group sell nonvoting equity security pre viously hold series transaction addition nonvoting equity security utilise disetronic transaction note utilise conversion helveticus bond note group agree counterpartie restructure previous arrangement writtenshort option purchasedlong option strike price combine effect forward purchase december arrangement close addition group pur chase counterpartie low exercise price option lepos group right purchase nonvoting equity security low strike price note roche group consolidated financial statementsconsequently group follow holding equity instrument equivalent num ber nonvoting equity security december december nonvoting equity security low exercise price option forward purchase derivative instrument total nonvoting equity instrument equity instrument record equity original cost acquisition detail equity instrument hold december show table fair value dis close information purpose equivalent number fair value nonvoting strike price million equity security maturity chf chf nonvoting equity security low exercise price option feb apr derivative instrument roche option plan feb feb options feb apr total nonvoting equity security low exercise price option hold potential conversion obligation arise group convertible debt instrument note group potential obligation employee roche option plan note cover option exercisable time maturity group hold resid ual number option purchase use group previous option compensation scheme close note december amount record debt forward contract purchase nonvoting equity security december million swiss franc amount record financial longterm asset collateral cover forward purchase december million swiss franc net cash outflow transaction equity instrument refinance instrument cover convertible debt obligation million swiss franc net cash outflow transaction equity instrument mil lion swiss francs netcash inflow million swiss franc group hold share note roche group consolidate financial statement earning share nonvoting equity security basic earning share nonvoting equity security continue business group net income millions chf number share million number nonvoting equity security millions weight average number nonvoting equity security hold million weight average number share nonvoting equity security issue calculate basic earning share millions basic earning share nonvoting equity security chf dilute earning share nonvoting equity security calculation dilute earning share nonvoting equity security net income weight average number share nonvoting equity security outstanding adjust effect dilutive potential share nonvoting equity security potential dilutive effect arise convertible debt instrument employee stock option plan outstanding convertible debt instrument convert lead reduction interest expense increase number share havea net dilutive effect earning share exercise outstanding vested employee stock option dilutive effect exercise outstanding vested genentech employee stock option dilutive effect net income genentech positive diluted earning share nonvoting equity security show potential impact ofthese dilutive effect earning share figure continue business group net income millions chf elimination interest expense net tax convertible debt instrument dilutive millions chf increase minority share group net income net tax assume outstanding genentech stock option exercise millions chf net income calculate diluted earning share million chf weight average number share nonvoting equity security issue million adjustment assume conversion convertible debt instrument dilutive million weight average number share nonvoting equity security issue calculate dilutive earning share millions diluted earning share nonvoting equity security chf note roche group consolidate financial statement fair value reserve million chf fair value fair value reserve reserve available qualifying equity currency forsale cash flow conversion translation investment hedge option reserve total total beginning year change fair value recognise net income defer income taxis minority interest currency translation gain loss end year minority interest millions chf beginning year chugai acquisition disposal nippon roche disposal vitamin fine chemical minority share group net income net tax net effect movement fair value charge credit equity net effect exercise genentech stock option genentech stock repurchase chugai stock repurchase chugai dividend payment currency translation effect end year genentech chugai total minority interest relate party million chf control shareholder share capital roche holding ltd group parent company consist bearer share base information supply shareholder group pool voting right comprise lukas hoffmann vera michalskihoffmann maja hoffmann mrandr hoffmann andreas oeri sabine duschmaloeri catherine oeri beatrice oeri maja oeri fritz gerber group hold share precede year represents issue share figure include share pooled voting right hold outside group individual member group andr hoffmann andreas oeri fritz gerber members board director roche holding ltd capacity receive annual remuneration thousand swiss franc addition hoffmann oeri receive thousand swiss franc thousand swiss franc respectively time expense relate membership board com mittee gerber receive benefit roche pension fund receipt annual pension group pension thousand swiss franc supplementary information give group corporate gover nance disclosure page note roche group consolidate financial statement transaction group individual member shareholder group subsidiary associate company list major group subsidiary associate company include note trans action parent company subsidiary subsidiary eliminate consolidation transaction group associate company follow income statement income sale good supply service expense purchase good supply service milestone upfront payment balance sheet trade account receivable key management personnel member board director roche holding ltd receive annual remuneration thousand swiss franc thousand swiss franc time expense relate membership board committee total payment nonexecutive director remuneration expense million swiss franc million swiss franc payment humer member executive committee include figure executive committee member executive committee receive total remuneration show table salary bonus total cash remuneration pay option award pension social insurance contribution pay group supplementary information give group corporate governance disclosure page cash flow statement million chf cash flow operating activity cash flow operating activity derive group primary activity describe divisional review calculate indirect method adjust group operate profit operating income expense cash flow example depreciation amortisation impairment order derive cash generate operation operate cash flow show cash flow statement operate cash flow include income taxis pay activity include example taxis pay gain labcorp share sale note roche group consolidate financial statement net income add nonoperate income expense income associate company financial income exceptional impairment financial asset income taxis income applicable minority interest operate profit depreciation property plant equipment amortisation goodwill amortisation intangible asset impairment longterm asset change group organisation chugai transaction writeoff fair value adjustment inventory charge vitamin case major legal case expense define benefit postemployment plan adjustment cash generate operation cash flow financing activity cash flow financing activity primarily proceed issue repayment group equity debt instrument include interest payment dividend payment instrument cash flow shortterm financing include finance lease include cash flow indicate group transaction provider equity debt financing cash flow shortterm borrowing show net movement consist large number transaction short maturity interest dividend pay interest pay dividend pay total cash flow invest activity cash flow invest activity principally arise group investment inproperty plant equipment intangible asset acquisition divestment subsidiary associate company business cash flow connected group portfolio marketable security investment include interest anddividend payment receive respect security investment cash flow indicate group net reinvestment operate asset cash flow effect change group organisation cash generate group investment cash flow marketable security include income capital gain loss show net movement group portfolio consist large number position hold longterm basis cash flow labcorp transaction note show separate line cash flow statement cash flow respect chugai consist cash payment roche party cash hold chugai acquire note roche group consolidate financial statement interest dividend receive interest receive dividend receive total significant noncash transaction significant noncash investing financing transaction include nonvoting equity security disetronic acquisition note dsm share acquire disposal vitamin fine chemical business note nonvoting equity security conversion helveticus bond note subsequent event artus january group acquire interest artus gmbh artus million swiss franc million swiss franc pay december additional pay capital artus german biotechnology company develop product detection pathogen group right appoint member supervisory board artus accordingly artus report associate company igen january igen receive clearance relevant regulatory authority call extraordinary general meeting february approve acquisition igenby group approve igen shareholder receive usd share share bioveris stock new public company spunoff igen connection propose acquisition igen group contribute million dollar igen transfer bioveris purchase igen share million dollar give total cashoutflow million dollar note note roche group consolidated financial statement subsidiary associate company list company share capital country company city currency millions switzerland roche holding ltd basel chf stock exchange zurich valor share valor genussscheine isin share isin genussscheine market capitalisation chf usa cidgenentech inc south san francisco usd stock exchange new york incorporate isin delaware share market capitalisation usd usa cidtripath imaging inc burlington usd stock exchange nasdaq national isin share market capitalisation usd japan cidchugai pharmaceutical ltd tokyo jpy stock exchange tokyo isin share market capitalisation jpy canada cid isotechnika inc edmonton cad stock exchange toronto isin share market capitalisation cad great britain cidantisoma plc london gbp stock exchange london isin share market capitalisation gbp non list company share capital country company city currency millions argentina producto roche qumica industrial buenos aire ars australia roche diagnostic australia pty limited castle hill aud roche product pty limited dee aud syntex australia limited north sydney aud austria roche austria gmbh vienna eur roche diagnostic gmbh vienna eur bangladesh roche bangladesh ltd dhaka bdt belgium roche brussels eur roche diagnostic belgium brussels eur bermuda canadian pharmholding ltd hamilton usd corange international ltd hamilton usd corange ltd hamilton usd roche capital management ltd hamilton usd roche capital transaction limited hamilton usd roche financial product limit hamilton usd roche financial services ltd hamilton usd roche healthcare limited hamilton usd roche international finance bermuda ltd hamilton usd roche international ltd hamilton usd roche intertrade ltd hamilton usd roche services holdings ltd hamilton usd syntex pharmaceuticals international ltd hamilton usd brazil produto roche qumico farmacuticos paulo brl roche diagnostic brasil ltda paulo brl note roche group consolidate financial statement share capital country company city currency millions canada chempharm limited toronto cad hoffmannla roche limited toronto cad roche diagnostic ltd quebec cad sapac corporation ltd john chile producto roche ltda santiago chile clp china roche diagnostic hong kong limited hong kong hkd roche diagnostic shanghai limited shanghai usd roche hong kong limited hong kong hkd roche shanghai management ltd shanghai usd cid shanghai roche pharmaceuticals limited shanghai usd colombia producto roche bogot cop costa rica producto roche san jos usd roche servicios san jos usd czech republic roche sro prague czk denmark roche hvidovre dkk dominican republic producto roche dominicana santo domingo dop ecuador roche ecuador quito usd egypt roche egypt sae giza egp ropharm limited giza egp salvador productos roche salvador san salvador usd finland roche espoo eur france hoffmannla roche france sas neuillysurseine eur laboratoire roche nicholas sas gaillard eur roche diagnostic meylan eur roche neuillysurseine eur germany consulab mannheim gmbh mannheim eur corange deutschland hold gmbh mannheim eur disetronic medical system gmbh sulzbach eur galenus mannheim gmbh mannheim eur hestia health care gmbh mannheim eur hoffmannla roche aktiengesellschaft grenzachwyhlen eur roche consumer health deutschland gmbh eppstein eur roche deutschland hold gmbh grenzachwyhlen dem roche diagnostic gmbh mannheim eur great britain roche diagnostic ltd lewes gbp roche hold limited welwyn garden city gbp roche product limit welwyn garden city gbp roche registration limited welwyn garden city gbp greece roche hellas athens eur guatemala producto roche guatemala guatemala city gtq guernsey disetronic finance jersey ltd peter port chf roche capital market international limited peter port chf roche financial market limited peter port chf roche international finance corporation limited peter port chf honduras producto roche honduras tegucigalpa hnl hungary roche hungary ltd budapest huf india roche diagnostic india pvt ltd mumbai inr roche scientific company india private limited mumbai inr indonesia roche indonesia jakarta idr ireland roche ireland limited clarecastle eur roche products ireland limited dublin eur italy roche diagnostic spa milan eur roche spa milan eur japan roche diagnostic tokyo jpy luxembourg pharminvest luxembourg eur malaysia roche diagnostic malaysia sdn bhd kuala lumpur myr roche malaysia sdn bhd kuala lumpur myr mexico grupo roche syntex mxico mexico city mxn lakeside mxico mexico city mxn productos roche mexico city mxn syntex mexico city mxn morocco roche immobilire maroc sarl casablanca mad cid roche casablanca mad note roche group consolidate financial statementsshare capital country company city currency millions netherland disetronic medical system vianen eur roche diagnostic nederland almere eur roche finance europe woerden eur roche nederland woerden eur roche pharmholde woerden eur new zealand roche diagnostic new zealand pty ltd auckland nzd roche product new zealand limited auckland nzd nicaragua productos roche nicaragua managua nio norway roche norge oslo nok pakistan roche pakistan ltd karachi pkr panama producto roche interamericana panama city usd producto roche panam panama city pab roche capital corporation panama city roche financial management inc panama city chf syntex corporation panama city usd peru producto roche qumica farmacutica lima pen philippine roche philippines inc makati php poland roche diagnostic polska warsaw pln roche polska warsaw pln portugal roche farmacutica qumica lda amadora eur roche sistemas diagnsticos sociedade unipessoal lda lindaavelha eur puerto rico syntex puerto rico inc humacao usd russia roche moscow ltd moscow rub singapore boehringer mannheim far east pte ltd singapore sgd roche diagnostic asia pacific pte ltd singapore sgd roche singapore pte ltd singapore sgd south africa roche product proprietary limited johannesburg zar south korea roche diagnostics korea ltd seoul krw roche korea company ltd seoul krw spain andreu roche madrid eur boehringer mannheim roche madrid eur roche diagnostic barcelona eur roche farma madrid eur syntex roche madrid eur sweden disetronic medical systems nacka strand sek roche stockholm sek roche diagnostic scandinavia bromma sek switzerland disetronic handel burgdorf chf disetronic holding burgdorf chf disetronic licensing burgdorf chf disetronic medical systems burgdorf chf hoffmannla roche ltd basel chf imib insitute medical informatics biostatistics ltd basel chf pharmexbio ltd zug chf roche consumer health ltd kaiseraugst chf roche diagnostic schweiz ltd rotkreuz chf roche diagnostic international ltd steinhausen chf roche finanz basel chf roche instrument center ltd rotkreuz chf roche kapitalmarkt basel chf roche pharma switzerland ltd reinach chf roche treasury management europe ltd basel chf syntex corporation basel chf valorfide chur chf cid basilea pharmaceutica ltd basel chf cid rabbitair ltd zurichkloten chf taiwan roche diagnostics ltd taipei twd roche products ltd taipei twd thailand roche diagnostic thailand limited bangkok thb roche thailand limited bangkok thb turkey roche diagnostik sistemleri ticaret istanbul trl roche mstahzarlari sanayi anonim sirketi istanbul trl uruguay roche international ltd montevideo sapac corporation ltd montevideo note roche group consolidated financial statement share capital country company city currency millions usa american roche international inc little fall cad disetronic medical systems inc paul usd hoffmannla roche inc nutley usd roche carolina inc florence roche colorado corporation boulder usd roche diagnostic corporation indianapoli usd roche holdings inc wilmington usd roche laboratories inc nutley roche molecular systems inc pleasanton roche palo alto llc palo alto usd cidbayer roche llc morristown usd venezuela producto roche caracas veb group hold interest company list exception mark follow cid group company group interest fully consolidated cid joint venture group interest method proportionate consolidation cid associate company group interest equity method consolidation share capital show million local currency share capital local currency unit note roche group consolidate financial statementsreport group auditor general meeting roche holding ltd basel auditor group audit roche group consolidated financial statement consolidated income statement consolidate balance sheet consolidate statement change equity consolidated cash flow statement consolidate note page year end december consolidated financial statement responsibility board director roche holding ltd responsibility express opinion consolidated financial state ment base audit confirm meet swiss legal requirement concern professional qualification independence audit conduct accordance auditing standard promulgate swiss pro fession international standard auditing require audit plan perform obtain reasonable assurance consolidated financial state ment free material misstatement examine test basis evidence support ing amount disclosure consolidated financial statement assess accounting principle significant estimate overall consolidated financial statement presentation believe audit provide reasonable basis opinion opinion consolidate financial statement roche group present fairly material respect financial position december result operation cash flow year end accordance international financial reporting standard ifrs comply swiss law recommend consolidated financial statement submit approve pricewaterhousecoopers clive bellingham matthias jeger basel february report group auditor multiyear overview statistic report statement income millions chf sale ebitda operating profit net income research development balance sheet million chf longterm asset current asset total asset equity minority interest noncurrent liability current liability addition property plant equipment personnel number employee end year key ratio net income sale net income equity research development sale current ratio equity minority interest total asset sale employee thousand chf data share nonvoting equity security number share number nonvoting equity security genussscheine total share nonvoting equity securities total dividend million chf earning share nonvoting equity security dilute chf dividend share nonvoting equity security chf cash warrant addition dividend adjust chf cash warrant addition dividend unadjuste chf information table state report change accounting policy arising change international financial reporting standard andthe stock split arenot apply retrospectively warrant hold final exercise date addition normal dividend shareholder approve share nonvoting equity security special centenary warrant worth chf date issue holder option cash equivalent chf net income relate key ratio show special charge million swiss franc net tax incur follow corange acquisition include corange respect balance sheet datum multiyear overview warrant hold final exercise date dividend include special dividend relate spinoff fragrance flavour division dividend propose board director sale reduce million swiss franc reclassification cash discount note consolidated financial statement ebitda restate format financial statement exceptional item multiyear overview sale division millions chf pharmaceutical diagnostic vitamin fine chemical fragrance flavour total sale geographical area millions chf switzerland european union rest europe europe north america latin america japan rest asia asia africa australia oceania total sale reduce million swiss franc reclassification cash discount note consolidated financial statement multiyear overviewaddition property plant equipment division millions chf pharmaceutical diagnostic vitamin fine chemical fragrance flavour total addition property plant equipment geographical area millions chf switzerland european union rest europe europe north america latin america japan rest asia asia africa australia oceania total multiyear overview roche security share price performance chf roche share adjust swiss market index rebase nonvoting equity security genussschein price performance chf roche nonvoting equity security adjust swiss market index rebase american depositary receipt adr price performance usd roche adr adjust index rebase roche american depositary receipt adr equivalent nonvoting equity security genussschein adrs trade united states overthecounter market july roche securitiesnumber share nonvoting equity securitiesa number share nominal value chf chf number nonvoting equity security genussscheineno nominal value total datum share nonvoting equity securityin chf net income equity dividend stock price shareb high low yearend stock price nonvoting high equity security low genussscheinb yearend historic stock price unadjuste share yearend nonvoting equity security genussschein yearend market capitalisation millions chf yearend key ratio yearend net income equity dividend yield share dividend yield nonvoting equity security genussscheinein priceearning share priceearning nonvoting equity security genussscheine nonvoting equity security genussscheinconfer right share participate avail able earning remain proceed liquidation follow repayment nominal value share participation certificate capital share nonvoting equity security list swiss exchange roche holding ltd restriction ownership share nonvoting equity securities stock price datum reflect daily closing price stock price figure prior june adjust effect givaudan spinoff adjustment factor share nonvoting equity security factor independent financial institution net income share market capitalisation figure assume equity instrument hold outstanding dividend include special dividend relate spinoff fragrance flavour division dividend propose board director ticker symbol share nonvoting american equity security depositary receipt reuter roczs roczgs rhhbypk bloomberg rog rhhby swx swiss exchange rog roche security roche holding ltd basel financial statement income statement millions chf income income participation interest income loan group company interest investment income income total income expense financial expense administration expense loss disposal participation depreciation participation expense total expense profit year taxis tax net profit year financial statementsbalance sheet december millions chf longterm asset participation loan group company total longterm asset current asset account receivable group company account receivable prepay expense accrue income marketable security liquid fund total current asset total asset equity share capital nonvoting equity security genussscheine general legal reserve free reserve special reserve available earning balance bring forward previous year net profit year total equity noncurrent liability provision loan group company total noncurrent liability current liability account payable group company liabilitie accrue liability total current liability total liability total equity liability pro memoria nonvoting equity security nominal value financial statement note financial statement general financial statement roche holding ltd basel prepare accordance provision swiss company law accept business principle valuation method translation foreign currency balance sheet asset liability disclose net realisable value exception tothis rule participation show acquisition value appropriate writedown marketable security show low cost market value unrealise foreign currency gain balance sheet item defer expense income aswell foreign currency transaction translate exchange rate rule relevant transaction date detail specific item income total income million swiss franc million swiss franc higher previous year mainly high dividend income taxis tax charge include corporate income capital taxis withhold taxis stamp duty equity total equity equal previous year total asset change previous year disetronic acquisition increase participation loan group company movement equity show table million swiss franc general share legal free special available total capital reserve reserve reserve earnings equity january net income dividend pay transfer free reserve december net income dividend pay transfer free reserve december net income dividend pay transfer free reserve december note financial statementsshare capital previous year share capital amount million swiss franc share capital consist bearer share nominal value swiss franc include equity nonvoting equity security genussscheine share capital confer voting right nonvoting equity security genussschein confer right share participate available earning inany remain proceed liquidation follow repayment theshare capital guarantee guarantee favour group company total million swiss franc previous year mil lion swiss franc time prepare balance sheet risk arise contingent liability discernible convertible option reference note consolidated financial statement equity instrument reference note consolidated financial statement pledge asset asset total book value million swiss franc previous year pledge security company commitment participation major participation list page important shareholder share company bearer share reason company notkeep aregister shareholder follow figure base information shareholder theshareholder validation check annual general meeting april onother information available company previous year share shareholder group pool voting right comprise lukas hoffmann vera michalskihoffmann maja hoffmann andr hoffmann andreas oeri sabine duschmaloeri catherine oeri beatrice oeri msmaja oeri fritz gerbera previous year share participation novartis international ltd basel include affiliate thereofb information supply shareholder figure share include share pooled voting right hold outside group individual member group figure december supply novartis international ltd basel note financial statement appropriation available earning proposal general meeting chf available earning net profit year balance bring forward previous year total available earning appropriation available earning distribution ordinary dividend chf gross share nonvoting equity securitygenussschein chf year transfer free reserve total appropriation available earning carry forward account appropriation available earningsreport statutory auditor general meeting roche holding ltd basel statutory auditor audit accounting record financial statement income statement balance sheet note page roche holding ltd basel fortheyear end december financial statement responsibility board director responsibility toexpress opinion financial statement base audit confirm meet legal requirement concern professional qualification independence audit conduct accordance auditing standard promulgate swiss profession require audit plan perform manner obtain reasonable assurance financial statement free material mis statement examine test basis evidence support amount disclosure inthefinancial statement assess accounting principle significant estimate overall financial statement presentation believe audit pro vide areasonable basis opinion opinion accounting record financial statement propose appropriation available earning comply swiss law company article incorporation recommend financial statement submit approve ernst young ltd conrad lffel jrg zrcher basel february report statutory auditor arctic circle tropic cancer tropic capricorn roche rcrc letic global market presence sale switzerland manufacture argentina research development australia toe mic rii party austria bangladesh belgium bermuda brazil canada chile china colombia costa rica czech republic denmark dominican republic ecuador egypt salvador finland france germany great britain greece guatemala roche global market presence arctic circle tropic cancer tropic capricorn cnt rcrc letic guernsey south africa honduras south korea hungary spain india sweden indonesia taiwan ireland thailand italy turkey japan uruguay luxembourg usa malaysia venezuela mexico morocco netherlands new zealand nicaragua norway pakistan panama peru philippine poland portugal puerto rico russia singapore roche global market presence cautionary statement forwardlooke statement annual report contain certain forward opment economic condition delay look statement forwardlooke inability obtain regulatory approval bring statement identify byword ing product market fluctuation currency believe expect anticipate project intend exchange rate general financial market seek estimate future similar condition uncertainty discovery devel expression discussion opment market new product new use thing strategy goal plan intention exist product increase government factor cause actual result differ materially price pressure interruption production future reflect forwardlook loss inability obtain adequate protection ing statement contain annual report intellectual property right litigation price product initiative loss key executive orother employee ofcompetitor legislative regulatory devel adverse publicity news coverage publish hoffmannla roche ltd basel switzerland tel fax medium office corporate communication basel switzerland tel fax investor relations basel switzerland tel fax world wide web httpwwwrochecom order tel fax publication email baselwebmasterrochecom annual general meeting april trademark mention enjoy legal protection roche annual report publish german original language english roche annual report issue hoffmannla roche ltd basel corporate communication design wirz corporate zurich source associates zurich photo mike frei zurich roche corporate photolibrary basel typeset staufferfebel basel lithos lithoteam allschwilbasel printer birkhusergbc reinachbasel bind buchbinderei grollimund reinachbasel cover urogenital disease ureanaclalbumin crystal polarise microscopydiagnostic sale division pharmaceutical asia latin america sales region north america europe diagnostic employee division pharmaceutical latin america asia north america employee region europe continue business